

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



BA

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : A61K 47/48		A1	(11) International Publication Number: WO 00/01417 (43) International Publication Date: 13 January 2000 (13.01.00)
(21) International Application Number: PCT/GB99/01957 (22) International Filing Date: 22 June 1999 (22.06.99) (30) Priority Data: 9814527.9 3 July 1998 (03.07.98) GB		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(71) Applicant (for all designated States except US): CYCLACEL LIMITED [GB/GB]; 5 Whitehall Crescent, Dundee DD1 4AR (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): FISCHER, Peter, Martin [CH/GB]; Denley Lodge, 1 Arbirlot Road, Arbroath, Angus DD11 2EN (GB). WANG, Shudong [AU/GB]; Balmuir Farm Cottage, Tealing DD4 0QY (GB). (74) Agent: NACHSHEN, Neil, Jacob, D. Young & Co, 21 New Fetter Lane, London EC4A 1DA (GB).		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: DELIVERY SYSTEM (57) Abstract <p>The present invention relates to a novel drug delivery system of use in the improved delivery of drug therapeutic agents into target cells. The system comprises a drug moiety linked to a carrier moiety wherein the carrier moiety comprises a homeobox peptide or a fragment or derivative thereof.</p>			

FOR THE PURPOSES OF INFORMATION ONLY.

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

DELIVERY SYSTEMField of Invention

5 The present invention relates to a novel drug delivery system of use in the improved delivery of drug therapeutic agents into target cells. The delivery system provides other benefits that include enhancement in terms of the metabolism, distribution and excretion of the drug. The delivery system may be therapeutically active in both its intact and dissociated states.

10

Prior Art

The pharmaceutical industry has for many years concerned itself with the efficient delivery of therapeutic agents. This problem may be attributed to the short clearance 15 time of the agent in the body (short half-life), the location of the site of action or possibly the nature of the therapeutic agent itself, for example, its solubility, hydrophobicity etc.. Thus, many developments and strategies have been adopted, including formulating the therapeutic agent so as to protect it from a hostile environment on route to its site of action, by for example, enterically coated tablets, 20 controlled release devices and the like.

The development of peptide derived therapeutic agents has posed a further problem due their susceptibility to enzymatic degradation not only in the GI tract but also in the bloodstream. An example of how this problem has been addressed relates to the 25 incorporation of the peptides into liposomes or polymeric microspheres that target the peptides to the lymph system.

A further related problem, especially for therapeutic agents that function intracellularly is the barrier posed by the cell membrane. Thus, it may be possible to increase the half 30 life of the agent or ensure that it passes through the body without being degraded, but many agents must actually enter cells to exert their therapeutic effect.

European Patent 485578 discloses that the homeodomain and specifically, helix 3 of a homeobox peptide, particularly that derived from the *Drosophila Antennapedia*, is of use as an intracellular transport vector. The patent disclosed that a specific 57 amino acid sequence of a *Drosophila Antennapedia* homeopeptide (referred to as the pAntp peptide) was capable of penetrating fibroblasts and embryo cells (*in vivo*). Emphasis was placed upon the last 27 amino acids of the sequence that correspond with the helix 3 and 4. There is no description of the pAntp peptide being linked to any other peptide or therapeutic agent.

10

Subsequent disclosures (Derossi D et al., *J Biol Chem* (1994) 269, 10444-10450, Joliot AH et al., (1991) *The New Biol* 3, 1121-1134 and *PNAS* (1991) 88, 1864-1868, Perez F et al., *J Cell Sci* (1992) 102, 712-722), all disclose how a 16 amino acid synthetic peptide derived from the third helix of the *Antennapedia* homeodomain may be used 15 for the intracellular delivery of bioactive products and antisense oligonucleotides. The amino acid sequence of use is RQIKIWFQNRRMKWKK (SEQ ID No. 1) also known as Penetratin®.

In an effort to prevent the enzymatic cleavage of this peptide Brugidou J et al., 20 (*Biochem Biophys Res Comm* (1995) 214(2), 685-693) prepared a *retro-inverso* form (D amino acids in reverse order) of SEQ ID No. 1, substituting the two isoleucine resides at positions 3 and 5 of penetratin with valine and adding a glycine residue at the C-terminus to facilitate binding to a resin. A further *retro-inverso* form was prepared replacing the extra glycine with a cholesterol moiety attached via a sulphydryl 25 linker group. The addition of the cholesterol moiety improved penetration due to the increased hydrophobicity of the molecule.

This development of the *retro-inverso* form of penetratin has given rise to WO 97/12912 that discloses peptides of 16 amino acids comprising between 6 and 10 30 hydrophobic amino acids wherein the sixth amino acid from either end is tryptophan.

This disclosure attempts to define the minimal characteristics of sequences capable of acting as internalisation vectors.

Penetratin, its analogues and *retro-inverso* forms have therefore been described as
5 being of use as a carrier to facilitate the cellular internalisation of conjugated peptides
or oligonucleotides.

Summary of the Invention

10 The present invention aims to provide a delivery system for therapeutic drugs that is capable of facilitating the internalisation of the drug into cells, thus enhancing the delivery and/or therapeutic effect of the drug. The delivery system may also improve the half-life of the drug in the human or animal body, improve its solubility in biological fluids, minimise known toxic or non-desirable side-effects, enhance the
15 onset of action of the desired therapeutic effect, provide alternative routes for the administration of the drug, enhance the biodistribution and metabolism of the drug moiety and decrease the incidence of drug resistance.

Thus, the invention relates to a delivery system comprising a drug moiety linked to a
20 carrier moiety comprising a homeobox peptide or a fragment or derivative thereof. As is discussed hereinafter, the drug moiety is not a peptide or oligonucleotide and the carrier moiety may be a derivative of penetratin.

Brief Description of the Drawings

25 Figure 1 shows the stabilisation of microtubule formation by systems of the present invention.

Figure 2 shows the comparison of cell internalisation of a delivery system of the
30 present invention compared to the carrier moiety alone.

Figure 3 shows the internalisation of a delivery system of the present invention.

Figure 4 shows the intracellular stability of a delivery system of the present invention.

5 Description of the Preferred Embodiments

In a first embodiment, the delivery system comprises a drug moiety linked to a carrier moiety. The drug moiety may be directly or indirectly linked to the carrier moiety. In the preferred embodiment wherein the drug moiety is indirectly linked to the carrier, 10 the linkage may be by an intermediary bonding group such as a sulphhydryl or carboxyl group or any larger group, all such linking groups and others described below, are hereinafter referred to as linker moieties.

In accordance with the present invention, suitable drug moieties include any 15 therapeutically active non-peptide/oligonucleotide drug. Thus, the drug moiety may be selected from cytotoxic agents, anti-neoplastic agents, anti-hypertensives, cardioprotective agents, anti-arrhythmics, ACE inhibitors, anti-inflammatory's, diuretics, muscle relaxants, local anaesthetics, hormones, cholestrol lowering drugs, anti-coagulants, anti-depressants, tranquilizers, neuroleptics, analgesics such as a 20 narcotic or anti-pyretic analgesics, anti-virals, anti-bacterials, anti-fungals, bacteriostats, CNS active agents, anti-convulsants, anxiolytics, antacids, narcotics, antibiotics, respiratory agents, anti-histamines, immunosuppressants, immunoactivating agents, nutritional additives, anti-tussives, diagnostic agents, emetics and anti-emetics.

25

Preferably the drug moiety is a cytotoxic or anti-neoplastic agent, particularly those which are used for cancer therapy or such drug in photoactivatable form. Such drugs include, in general, DNA damaging agents, anti-metabolites, anti-tumour antibiotics, natural products and their analogues, dihydrofolate reductase inhibitors, pyrimidine 30 analogues, purine analogues, cyclin-dependent kinase inhibitors, thymidylate synthase inhibitors, DNA intercalators, DNA cleavers, topoisomerase inhibitors, anthracyclines,

vinca drugs, mitomycins, bleomycins, cytotoxic nucleosides, pteridine drugs, diynenes, podophyllotoxins, platinum containing drugs, differentiation inducers, and taxanes. Particularly useful members of those classes include, for example, methotrexate, methopterin, dichloromethotrexate, 5-fluorouracil, 6-mercaptopurine, tri-substituted 5 purines such as olomoucine, roscovitine, bohemine and purvalanol, flavopiridol, staurosporin, cytosine arabinoside, melphalan, leurosine, actinomycin, daunorubicin, doxorubicin, mitomycin D, mitomycin A, carinomycin, aminopterin, tallysomycin, podophyllotoxin (and derivatives thereof), etoposide, cisplatin, carboplatinum, vinblastine, vincristine, vindesine, paclitaxel, docetaxel, taxotere retinoic acid, butyric 10 acid, acetyl spermidine, tamoxifen, irinotecan and camptothecin. Most preferably the drug moiety is selected from methotrexate, podophyllotoxin (and derivatives thereof), etoposide, camptothecin, paclitaxel, doxorubicin, roscovitine and bohemine.

The carrier moiety as used in the present invention may be any moiety that is capable 15 of facilitating the cellular internalisation of the drug moiety. Suitable carrier moieties include homeobox peptides or derivatives thereof such as the helix 3 of a homeobox peptide. Preferably, the homeobox peptide is derived from the Drosophila Antennapedia homeoprotein, sequences homologous thereto or derivatives thereof. More preferably, the carrier moiety is penetratin or a derivative thereof. Derivatives of 20 penetratin have been described in the literature, for example EP 485578B, that discloses sequences homologous to pAntp. Further derivatives of penetratin that may be utilised in the present invention include truncated forms and/or modified forms of penetratin described in WO97/12912, UK Patent Applications 9825000.4 filed 13 November 1998 and 9902522.3 filed 4 February 1999 the contents of which are hereby 25 incorporated by reference. A preferred truncated form of penetratin is RRMKWKK (SEQ ID No. 2). Further truncated forms include moieties of upto 15 amino acid residues including the sequences such as NRRMKWKK, QNRRMKWKK and FQNRRMKWKK or more preferably a 7 amino acid peptide selected from KRMKWKK, RKMKWKK, RREKWKK, RRQKWKK, RROKWKK, RRMKQKK, 30 RRMKWFK, RORKWKK, RRMWKKK and RRMKKWK (using standard single amino acid notation, ornithine (O), diaminobutyric acid (B), norleucine (N)).

Within the carrier moieties defined as penetratin or derivatives thereof, a further modification that is beneficial in the context of the present invention is conversion of the free carboxyl group of the carboxy terminal amino acid residue, to an carboxamide group. By way of example, when the carrier moiety is penetratin (SEQ ID No. 1) the 5 carboxy terminal lysine residue may have its carboxyl group converted into an carboxamide group. This modification is believed to enhance the stability of the carrier moiety and hence the delivery system as a whole.

The carrier moiety may be in the L or D optically active form. As used herein, when 10 no indication is given, the carrier is in the L form. D-penetratin is described in Brugidou J et al., (Biochem Biophys Res Comm (1995) 214(2), 685-693). The carrier moiety may also be arranged in the *retro* form, i.e with the amino acid residues in the reverse order to their parent sequence. Such *retro* forms may also exist in L and D forms. Thus, in a further preferred embodiment the carrier moiety may be D- 15 penetratin or the D form of the truncated and/or modified forms discussed above.

The drug moiety may be attached to either end of the carrier moiety e.g. if the carrier moiety is penetratin as shown in SEQ ID No. 1 or a derivative thereof, the drug moiety may be directly or indirectly attached to the terminal lysine or arginine residues. 20 Preferably, the drug moiety is attached to the amino terminal end of the carrier.

As discussed above the drug and carrier moieties may be linked directly or indirectly via a linker moiety. Direct linkage may occur through any convenient functional group on the drug moiety such as a hydroxy, carboxy or amino group. Indirect linkage 25 which is preferable, will occur through a linking moiety. Suitable linking moieties include bi- and multi-functional alkyl, aryl, aralkyl or peptidic moieties, alkyl, aryl or aralkyl aldehydes acids esters and anyhrides, sulphydryl or carboxyl groups, such as maleimido benzoic acid derivatives, maleimido propionic acid derivatives and succinimido derivatives or may be derived from cyanuric bromide or chloride, 30 carbonyldiimidazole, succinimidyl esters or sulphonic halides and the like. The functional groups on the linker moiety used to form covalent bonds between linker and

drugs on the one hand, as well as linker and carrier moiety on the other hand, may be two or more of, e.g., amino, hydrazino, hydroxyl, thiol, maleimido, carbonyl, and carboxyl groups, etc. The linker moiety may include a short sequence of from 1 to 4 amino acid residues that optionally includes a cysteine residue through which the linker 5 moiety bonds to the carrier moiety.

Preferably, the linker moiety includes a cysteine residue that provides the actual linkage to the carrier moiety such as to form a linkage of the type drug-(linker-Cys)-carrier. Within the context of the specification this cysteine residue is considered as a 10 component of the linker moiety. Thus, the complete linker moiety may only be formed as a result of the drug-carrier coupling reaction as the cysteine residue component of the linker may be conveniently prepared as part of the carrier moiety. In a preferred embodiment the linker moiety is selected from (methylamino)benzoyl-Cys, succinimidobenzoyl-Cys, succinimidopropionyl-Cys, β -alanyl-succinyl, acetyl-Cys 15 and (4"-aminoanilino)-succinimidopropionyl-Cys. In such preferred embodiments, the cysteine residue preferably originates as a terminal residue of the carrier moiety, whereas the non-cysteine component of the linker is coupled to the drug moiety prior to reaction with the carrier. The complete linker moiety is therefore only formed upon reacting the drug and carrier moieties together.

20

In a manner identical to the inclusion of a cysteine residue into the linker moiety, further amino acid residues may be included in the linker which like the cysteine residue form the connection with the carrier moiety. For example, 3 or 4 amino acid residues may be included and these preferably include the cysteine residue discussed 25 above. Any amino acid residues may be included, it is however preferable to select the residues from cysteine, β -alanine and glycine. The inclusion of such residues is preferable, particularly including cysteine, when the carrier moiety is a truncated form of penetratin such as RRMKWKK.

30 In use, the delivery system may dissociate by way of chemical or enzymatic cleavage between the drug and carrier moieties. Within the embodiments wherein the linker

moiety includes amino acid residues, such cleavage may occur within the linker moiety itself.

In accordance with the present invention each carrier moiety is linked to at least one drug moiety. In a further embodiment, the carrier moiety is prepared such as to facilitate linkage to more than one drug moiety, each drug moiety being the same or different. For example, the carrier moiety may comprise components that themselves facilitate the attachment of more than one drug moiety such as derivatives of naturally occurring amino acids or insertion of a multi-valent synthetic amino acid, or it may be specifically adapted to do so for example by a network of branched lysine residues that may be attached to the carrier moiety as a linking group and each lysine residue may then be attached to a drug moiety. In this manner a single carrier moiety may carry up to 32 drug moieties, preferably from 2 to 10 or more preferably from 4 to 5 drug moieties. In this further embodiment each drug moiety may be directly or indirectly linked to the carrier moiety by the same or different linker moiety. When more than one different type of drug moiety is attached, it is possible to co-ordinate the ratios and dosages of the individual drugs to facilitate the administration of specific drug combinations.

Preferred examples of this embodiment include when the carrier moiety is penetratin with a network of lysine residues attached to at least one end facilitating the attachment of up to 32 drug moieties or when the carrier moiety is penetratin or a derivative thereof, such as SEQ ID No. 2 (truncated 7-mer), the linker moieties are succinimidopropionyl and the drug moieties are selected from podophyllotoxin (at both ends of the carrier moiety) or epipodophyllotoxin together with either camptothecin or paclitaxel.

In a particularly preferred embodiment of the invention, the carrier moiety is penetratin or a derivative thereof that is indirectly linked to a drug moiety selected from doxorubicin, methotrexate, podophyllotoxin (and derivatives thereof), etoposide, camptothecin, paclitaxel, doxorubicin, roscovitine and bohemine.

In a further embodiment of the invention, the delivery system may further comprise a targeting moiety. The targeting moiety is capable of directing the delivery system to the specific cell type to which it is preferable for the drug moiety to function. Thus, 5 the targeting moiety acts as an address system biasing the bodies natural distribution of drugs or the delivery system to a particular cell type. The targeting moiety may be attached to the drug moiety or more preferably to the carrier moiety.

Suitable targeting moieties include the peptide sequences identified by E Ruoslahti et 10 al. in US Patent 5,622,699; Pasqualini, R, Ruoslahti, E. *Nature* (London) (1996), 380, 364-366, Ruoslahti, E. *Ann. Rev. Cell Dev. Biol.* (1996), 12, 697-715; Arap, W, Pasqualini, R, Ruoslahti, E, *Science* (1998), 279, 377-380. These disclosures, which 15 are herein incorporated by reference, described certain peptides that have been found to act as address labels to certain cell types. Such peptides when attached to either the drug or more preferably, the carrier moiety will direct the delivery system, upon arrival at which the carrier moiety will facilitate the cellular internalisation of the drug moiety.

The delivery systems described herein are novel chemical entities. Specific chemical 20 entities disclosed herein include;

20

#	Drug moiety	Linker moiety	Carrier moiety
	(methotrexate) ₄	((methylamino)benzoyl-EG β A) ₄	(L) ₃ BARQIKIWFQNRRMKWKK-OH
	doxorubicin	succinimidobenzoyl-C	RQIKIWFQNRRMKWKK-OH
	doxorubicin	succinimidobenzoyl-C	(D-K)(D-K)(D-W)(D-K)(D-M)(D-R)(D-R)(D-N)(D-Q)(D-F)(D-W)(D-I)(D-K)(D-I)(D-Q)(D-R-NH ₂)
	paclitaxel	2'-succinimidopropionoyl-C	RQIKIWFQNRRMKWKK-OH
N-term C-term	paclitaxel	2'-succinimidopropionoyl-GCG β A	RQIKIWFQNRRMKWKK
	paclitaxel	2'-succinimidopropionoyl-C	RQIKIWFQNRRMKWKK-NH ₂
	paclitaxel	2'-succinimidopropionoyl-C β A	RRMKWKK-NH ₂
	paclitaxel	7-succinimidopropionoyl-C	RQIKIWFQNRRMKWKK-OH
	podophyllotoxin	4-succinimidopropionoyl-C	RQIKIWFQNRRMKWKK-OH
N-	podophyllotoxin	4-succinimidopropionoyl-	RQIKIWFQNRRMKWKK

term C-term	biotinamidocaproyl	GCG βA	
	podophyllotoxin	4-succinimidopropionyl-C	RQIKIWFQNRRMKWKK-NH ₂
	podophyllotoxin	4-succinimidopropionyl-C	(D-R)(D-Q)(D-J)(D-K)(D-I)(D-W)(D-F)(D-Q)(D-N)(D-R)(D-R)(D-M)(D-K)(D-W)(D-K)(D-K-NH ₂)
	podophyllotoxin	4-succinimidopropionyl-CβA	RRMKWKK-NH ₂
	podophyllotoxin	4-succinimidopropionyl-CβA	(D-R)(D-R)(D-M)(D-K)(D-W)(D-K)(D-K-NH ₂)
	epipodophyllotoxin	4'-succinimidopropionyl-C	RQIKIWFQNRRMKWKK-OH
	epipodophyllotoxin	4'-succinimidopropionyl-C	RQIKIWFQNRRMKWKK-NH ₂
	epipodophyllotoxin	4'-succinimidopropionyl-CβA	RRMKWKK-NH ₂
	4'-demethyl epipodophyllotoxin	4-succinimidopropionyl-C	RQIKIWFQNRRMKWKK-OH
	etoposide (G2, G3 and 4')	succinimidopropionyl-C	RQIKIWFQNRRMKWKK-OH
	roscovitine	succinimidopropionyl-C	RQIKIWFQNRRMKWKK-OH
	bohemine	βA-succinyl-βA	RQIKIWFQNRRMKWKK-OH
	bohemine	succinimidopropionyl-C	RQIKIWFQNRRMKWKK-OH
	podophyllotoxin	4-acetyl-C	RQIKIWFQNRRMKWKK-OH
	podophyllotoxin	4-acetyl-CβA	RRMKWKK-NH ₂
	4'-demethyl epipodophyllotoxin	4-acetyl-CβA	RRMKWKK-NH ₂
	4'-demethyl epipodophyllotoxin	4-acetyl-C	RQIKIWFQNRRMKWKK-NH ₂
	podophyllotoxin	4-succinimidopropionyl-GCβA	RRMKWKK-NH ₂
	camptothecin	10-O-succinimidopropionyl-C	RQIKIWFQNRRMKWKK-NH ₂
C-term N-term	podophyllotoxin podophyllotoxin	4-succinimidopropionyl-C 4-succinimidopropionyl-C	RRMKWKK
N-term C-term	epipodophyllotoxin camptothecin	4'-succinimidopropionyl-C 10-O-succinimidopropionyl-C	RRMKWKK
N-term C-term	epipodophyllotoxin paclitaxel	4'-succinimidopropionyl-C 2'-(succinimido)propionyl-C	RRMKWKK
	4'-methoxy-epipodophyllotoxin	4-(4"-aminoanilino)succinimidopropionyl-C	RQIKIWFQNRRMKWKK-NH ₂
	4'-methoxy-epipodophyllotoxin	4-(4"-aminoanilino)succinimidopropionyl-CβA	RRMKWKK-NH ₂
	4'-demethyl-epipodophyllotoxin	4-(4"-aminoanilino)succinimidopropionyl-CβA	RRMKWKK-NH ₂

The therapeutic effect resulting from the administration of the delivery system may arise from the intact delivery system or any of its dissociated components that include the drug moiety i.e the drug moiety alone or bound to the linker, part of the linker or 5 the linker and part of the carrier. Thus the term "delivery system" has been used herein to have its ordinary meaning i.e that of delivering something such as the drug moiety and additionally to include the system or any portion thereof as being active in its intact state. Thus, the benefits provided by the system discussed above are applicable to the drug and delivery system.

10

The delivery vectors may be prepared by any methods known in the art. For example, the pAntp peptide can be assembled using conventional solution- or solid-phase peptide synthesis methods, affording a fully protected precursor with only the terminal amino group in deprotected reactive form. This function can then be reacted directly 15 with a drug moiety or a suitable reactive derivative of a drug moiety. Alternatively, this amino group may be converted into a different functional group suitable for reaction with a drug moiety or a linker. Thus, e.g. reaction of the amino group with succinic anhydride will provide a selectively addressable carboxyl group, while further peptide chain extension with a cysteine derivative will result in a selectively 20 addressable thiol group. Once a suitable selectively addressable functional group has been obtained in the delivery vector precursor, a drug moiety or a derivative thereof may be attached through e.g. amide, ester, or disulphide bond formation. Alternatively, a linker group, e.g. *m*-maleimidobenzoyl, is introduced by reaction of a linker group precursor with the selectively addressable function of the delivery vector 25 precursor, followed by formation of a covalent bond between the linker group and a drug moiety. Multivalent drug-delivery vector constructs may be obtained, *inter alia*, by successive extension of the selectively addressable delivery vector precursor with trivalent chemical groups. Thus peptide chain extension with e.g. N^{a,b}-Fmoc-protected Lys derivatives will afford di-, tetra-, and octa-valent construct precursors after one, 30 two, or three coupling/Fmoc-deprotection cycles.

Using these methods, the skilled person will be capable of preparing a wide variety of drug-carrier conjugates utilising a variety of linker moieties. As exemplified below, an appropriate group on the drug moiety may be selected for attachment to the carrier moiety and if desired a linker joined to the drug or carrier moiety, or both prior to their 5 coupling.

The compounds of the present invention may be formulated with a physiologically acceptable diluent or carrier for use as pharmaceuticals for both veterinary, for example in mammals, and particularly human use by a variety of methods. For 10 instance, they may be applied as a composition incorporating a liquid diluent or carrier, for example an aqueous or oily solution, suspension or emulsion, which may often be employed in injectable form for parental administration and therefore may conveniently be sterile and pyrogen free. Oral administration may also be used and although compositions for this purpose may incorporate a liquid diluent or carrier, it is 15 more usual to use a solid, for example a conventional solid carrier material such as starch, lactose, dextrin or magnesium stearate. Such solid compositions may take the form of powders but are more conveniently of a formed type, for example as tablets, cachets, or capsules (including spansules). Alternative, more specialized types of formulation include liposomes and nanoparticles.

20 Other types of administration than by injection or through the oral route which are of use in both human and veterinary contexts include the use of suppositores or pessaries. Another form of pharmaceutical composition is one for buccal or nasal administration or administration to the airways such as alveolar tissue. Other formulations of topical 25 administration include lotions, ointments, creams, gels and sprays.

Compositions may be formulated in unit dosage form, i.e. in the form of discrete portions containing a unit dose, or a multiple or sub-unit of a unit dose.

30 As is described in the Examples below, the delivery system of the present invention provides several advantages over known delivery systems for non-peptide/oligonucleotide delivery systems. These advantages include improved efficacy

compared to conventional treatments, improved cellular uptake of the therapeutic agent, improved water solubility, reduction of side effects and cellular bioavailability and decreased occurrence of drug resistance.

5

Examples**Examples****10 Abbreviations**

Amino acid and peptide nomenclature conforms to IUPAC-IUB rules (*Eur. J. Biochem.* 1984, 138, 9-37). Other abbreviations: AcOH, acetic acid; Boc, *tert*-butyloxycarbonyl; Bu¹, *tert*-butyl; DE MALDI-TOF MS, delayed extraction matrix-assisted laser desorption ionisation time-of-flight mass spectrometry; DIC, 1,3-diisopropylcarbodiimide; DIEA, diisopropylethylamine; DMAP, 4-dimethylaminopyridine; DMEM, Dulbecco's modified Eagle medium; DMF, dimethylformamide; Et₃N, triethylamine; EtOAc, ethyl acetate; Et₂O, diethyl ether; FCS, foetal calf serum; HOBr, 1-hydroxybenzotriazole; MeCN, acetonitrile; MeOH, methanol; NMR, nuclear magnetic resonance spectroscopy; PE, petroleum ether 40 – 60 °C boiling fraction; PBS, phosphate-buffered saline; Pmc, 2,2,5,7,8-pentamethylchroman-6-sulfonyl; PyBOP, benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate; RP-HPLC, reversed-phase high-performance liquid chromatography; TFA, trifluoroacetic acid; Trt, triphenylmethyl.

25

General

RP-HPLC was conducted using Vydac 218TP54 (4.5 x 250 mm) and 218TP1022 (22 x 250 mm) columns for analytical and preparative purposes, respectively. Flow rates were 1 mL/min for analytical and 9 mL/min for preparative runs. Gradient elution (constant 25 °C) was performed using increasing amounts of MeCN in water

(containing a constant concentration of 0.1 % TFA) over 20 min (analytical) or 40 min (preparative). Flash chromatography was carried out as described (W. C. Still, M. Kahn, A. Mitra, *J. Org. Chem.*, 1978, 43, 2923-2925) using Merck silica gel 60, 230-240 mesh. Peptide synthesis was carried out using an ABI 433A Peptide Synthesizer 5 (Perkin-Elmer Applied Biosystems). Amino acid derivatives were from Novabiochem AG, Läufelfingen, Switzerland, except Fmoc-D-Ile-OH, which was from Bachem AG, Bubendorf, Switzerland. Standard synthesis protocols (0.1 mmol or 0.25 mmol scale "FastMoc MonPrevPk" programs) based on the Fmoc-protection strategy (G. B. Fields, R. L. Noble, *Intl. J. Peptide Protein Res.*, 1990, 35, 161) were applied. Peptidyl 10 resins were cleaved and deprotected using the following reagent: 0.75:0.5:0.5:0.25:10 (w/v/v/v/v) phenol, water, thioanisole, 1,2-ethanedithiol, TFA (D. S. King, C. G. Fields, G. B. Fields, *Intl. J. Peptide Protein Res.*, 1990, 36, 255). DE MALDI-TOF 15 MS was performed using a Dynamo (Thermo BioAnalysis, Hemel Hempstead, England) spectrometer. The matrix used was a-cyano-4-hydroxycinnamic acid. The spectrometer was calibrated using authentic peptides with appropriate masses. NMR spectra were recorded on a Brucker DPX300 instrument. Paclitaxel, podophyllotoxin, and 10-hydroxycamptothecin were from Hande Tech Development Co. USA Inc, Houston, TX, USA. 4'-Demethylepipodophyllotoxin was prepared as described (M. Kuhn, C. Keller-Juslén, A. von Wartburg, *Helv. Chim. Acta*, 1969, 52, 944). 20 Roscovitine was prepared essentially as described (L. Havlicek, J. Hanus, J. Vesely, S. Leclerc, L. Meijer, G. Shaw, M. Strnad, *J. Med. Chem.* 1997, 40, 408). Bohemine (6-(benzylamino)-2-[(3-(hydroxy-propyl)amino]-9-isopropylpurine) was synthesised similarly. Anhydrous DMF, ClCH₂CH₂Cl, and CH₂Cl₂, stored over molecular sieve 25 4A, were used throughout.

Example 1

H-Arg(Pmc)-Gln(Trt)-Ile-Lys(Boc)-Ile-Trp-Phe-Gln(Trt)-Asn(Trt)-Arg(Pmc)-Arg(Pmc)-Met-Lys(Boc)-Trp-Lys(Boc)-Lys(Boc)-resin

30 The peptide sequence was assembled on Fmoc-Lys(Boc)-[(4-(hydroxymethyl)phenoxyacetyl)-resin] (ABI 401425; 0.5 mmol/g). The final peptidyl


resin (1.37 g, 100 %) was washed with Et_2O and dried *in vacuo*. In order to demonstrate the chemical integrity of this intermediate, a small aliquot of peptidyl resin was cleaved and deprotected, followed by analysis of the crude product H-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-OH, which revealed 5 purity of > 90 % (anal. RP-HPLC) and chemical identity (DE MALDI-TOF MS and quantitative amino acid analysis).

[H-Glu(OBu¹)-Gly- β Ala]₄-Lys₂-Lys- β Ala-Arg(Pmc)-Gln(Trt)-Ile-Lys(Boc)-Ile-Trp-Phe-Gln(Trt)-Asn(Trt)-Arg(Pmc)-Arg(Pmc)-Met-Lys(Boc)-Trp-Lys(Boc)-Lys(Boc)-resin
10 The above peptidyl resin (137 mg, 25 μmol) was acylated with Fmoc- β Ala-OH (47 mg, 0.15 mmol), PyBOP (78 mg, 0.15 mmol), HOBr (20 mg, 0.15 mmol) and DIEA (39 μL , 0.225 mmol) in DMF (2 mL) during 2 h. It was then Fmoc-deprotected with 20 % piperidine in DMF for 20 min and washed extensively with DMF. The product 15 was further extended by two successive acylation and deprotection cycles using Fmoc-Lys(Fmoc)-OH (0.15 mmol in first cycle; 0.3 mmol in second cycle) using similar coupling and deprotection steps. This was followed by further chain extension with Fmoc-Gly-OH (0.6 mmol) and Fmoc-Glu(OBu¹)-OH (0.6 mmol), again using similar acylation and Fmoc-deprotection conditions. The product was Fmoc-deprotected and 20 washed extensively with DMF, CH_2Cl_2 and Et_2O , followed by drying *in vacuo*. In order to demonstrate chemical integrity of this intermediate, a small aliquot of peptidyl resin was cleaved and side-chain deprotected, followed by analysis of the crude product [H-Glu-Gly- β Ala]₄-Lys₂-Lys- β Ala-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-OH, which revealed purity (> 89 %; RP-HPLC, 15 – 25 % MeCN gradient, t_R = 17.7 min, λ = 200 - 300 nm) and identity (DE MALDI-TOF MS: $[\text{M} + \text{H}]^+ = 3732$, $\text{C}_{165}\text{H}_{269}\text{N}_{53}\text{O}_{44}\text{S} = 3731.30$).

{[4[N-(2,4-diamino-6-pteridinyl-methyl)-N-methylamino]benzoyl]-Glu(OBu¹)-Gly- β Ala}₄-Lys₂-Lys- β Ala-Arg(Pmc)-Gln(Trt)-Ile-Lys(Boc)-Ile-Trp-Phe-Gln(Trt)-Asn(Trt)-Arg(Pmc)-Arg(Pmc)-Met-Lys(Boc)-Trp-Lys(Boc)-Lys(Boc)-resin
30

The above peptidyl resin (76 mg, 25 μ mol) was reacted overnight at room temperature with 4[N-(2,4-diamino-6-pteridinyl-methyl)-N-methylamino]benzoic acid hemihydrochloride dihydrate (76 mg, 0.2 mmol) and PyBOP (104 mg, 0.2 mmol), HOBt (27 mg, 0.2 mmol) and DIEA (70 μ L, 0.4 mmol) in DMF (2 mL). The product was washed successively with DMF, CH_2Cl_2 and Et_2O and dried *in vacuo* to afford the title compound (85 mg orange peptidyl resin).

{[4[N-(2,4-Diamino-6-pteridinyl-methyl)-N-methylamino]benzoyl]-Glu-Gly-
10 β Ala}₄-Lys₂-Lys- β Ala-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-OH




The above product was cleaved and deprotected (12 mL cleavage reagent, 1.5 h). Resin residue was then filtered off and washed on a sinter with small aliquots of neat TFA. The combined filtrate and washings were treated with Et_2O (100 mL) and cooled. The precipitated product was collected by centrifugation and the ethereal supernatant was decanted. The product was washed three more times with Et_2O in a similar fashion. The final crude product was dried *in vacuo* (61 mg orange powder). This material was redissolved in 0.1 % aq TFA (4 mL) and filtered. The resulting solution was applied (two separate runs) to a preparative RP-HPLC column (17.5 - 27.5 % MeCN gradient runs). Peak fractions were collected, monitored (analytical RP-HPLC) and pooled as appropriate. After vacuum centrifugation, pure title compound (13.5 mg) was obtained. Anal. RP-HPLC: t_R = 17.8 (17.5 - 27.5 % MeCN gradient; purity > 99 %, λ = 200 - 300 nm). DE MALDI-TOF MS: $[\text{M} + \text{H}]^+ = 4962$ ($\text{C}_{225}\text{H}_{321}\text{N}_{81}\text{O}_{48}\text{S} = 4960.54$).

Example 2

H-Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-OH

5 H-Arg(Pmc)-Gln(Trt)-Ile-Lys(Boc)-Ile-Trp-Phe-Gln(Trt)-Asn(Trt)-Arg(Pmc)-
Arg(Pmc)-Met-Lys(Boc)-Trp-Lys(Boc)-Lys(Boc)-resin (see example 1; 411 mg, 75
μmol) was acylated with Fmoc-Cys(Trt)-OH (264 mg, 0.45 mmol), PyBOP (234 mg,
0.45 mmol), HOBr (61 mg, 0.45 mmol) and DIEA (0.12 mL, 0.675 mmol) in DMF (3
mL) during 3 h. The resulting peptidyl resin was washed with DMF (3 x 5 min, 25 mL
10 each), drained and treated with 20 % piperidine in DMF during 20 min. After filtration
of the reagent, the product H-Cys(Trt)- Arg(Pmc)-Gln(Trt)-Ile-Lys(Boc)-Ile-Trp-Phe-
Gln(Trt)-Asn(Trt)-Arg(Pmc)-Arg(Pmc)-Met-Lys(Boc)-Trp-Lys(Boc)-Lys(Boc)-resin
was washed successively with DMF, CH₂Cl₂ and Et₂O, before being dried *in vacuo*.
This product was cleaved/deprotected (2 h). Resin residue was then filtered off and
15 washed on a sinter with small aliquots of neat TFA. The combined filtrate and
washings were treated with Et₂O (100 mL) and cooled. The precipitated product was
collected by centrifugation and the ethereal supernatant was decanted. The product was
washed three more times with Et₂O in a similar fashion. The final crude product was
dried *in vacuo* (238 mg). An aliquot (119 mg) of this material was redissolved in 0.1 %
20 aq TFA (2 mL) and filtered. The resulting solution was purified by preparative RP-
HPLC (17.5 - 27.5 % MeCN gradient). Peak fractions were collected, monitored
(analytical RP-HPLC) and pooled as appropriate. After vacuum centrifugation, pure
title compound (60.9 mg) was obtained. Anal. RP-HPLC: t_R = 15.8 min (17.5 - 27.5 %
MeCN gradient; purity > 99 %, λ = 214 nm). DE MALDI-TOF MS: [M + H]⁺ = 2351
25 (C₁₀₇H₁₇₃N₃₅O₂₁S₂ = 2349.87).

N-[3-(Maleimido)benzoyl]doxorubicin



Doxorubicin hydrochloride (5.9 mg, 10 μ mol) was dissolved in water (1 mL) and


DMF (0.5 mL). Buffer (0.1 M aq phosphate, pH 7.2; 0.5 mL) was added with stirring.

To the resulting suspension 3-maleimidobenzoic acid *N*-hydroxysuccinimide ester

5 (12.9 mg, 40 μ mol) in DMF (1 mL) was added dropwise. The red-coloured reaction mixture cleared temporarily and after *ca.* 10 min precipitation was observed. Reaction progress was monitored by anal. RP-HPLC and after 2 h all doxorubicin had reacted. The mixture was then diluted with H_2O (1.5 mL), cooled to 4 $^{\circ}C$ and centrifuged. The supernatant was decanted. The residual pellet was redissolved in DMF (1 mL) and 10 diluted with 0.1 % aq TFA (2 mL). This solution was applied to a solid-phase extraction cartridge (Merck LiChrolut RP-18, 500 mg; preconditioned successively with MeOH and 0.1 % aq TFA); the cartridge was washed with 0.1 % aq TFA (4 mL) and eluted with 6:4 MeCN/ H_2O (containing 0.1 % TFA) in two fractions (2 x 4 mL). The first fraction contained the title compound and was used directly in the next step.

15

N-(3-[3-(H-Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-OH)succinimido]benzoyl)doxorubicin



The above *N*-(3-(maleimido)benzoyl)doxorubicin solution was diluted with DMF (1


20 mL) and Et_3N (50 μ L) was added. The solution turned dark brown. H-Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-OH (5 mg), dissolved in DMF (1 mL) was then added. The mixture was stirred and the brown colour was observed to discharge, leaving a light red solution. The reaction was monitored by anal. RP-HPLC. After 1.5 h, all 3-(maleimido-benzoyl)doxorubicin had reacted. The 25 solution was acidified with AcOH (0.5 mL), diluted with water (3 mL) and applied to a

pre-conditioned solid-phase extraction cartridge (Merck LiChrolut RP-18, 500 mg). The cartridge was washed with 0.1 % aq TFA (6 mL) and eluted (6 mL of 6:4MeCN/water (containing 0.1 % TFA)). The eluate was dried by vacuum centrifugation. The residue was redissolved in 0.1 % aq TFA (2 mL), filtered and 5 purified by preparative RP-HPLC (20 - 40 % MeCN gradient). Peak fractions were collected, monitored (analytical RP-HPLC) and pooled as appropriate. After vacuum centrifugation, pure title compound (1.2 mg) was obtained. Anal. RP-HPLC: t_R = 15.6 & 15.8 min (partly resolved thioether diastereomers) (0 - 60 % MeCN gradient; purity > 95 %, λ = 200 - 300 nm). DE MALDI-TOF MS: $[M + H]^+ = 3094$, $[M + 2 H]^{2+} =$ 10 1548 ($C_{145}H_{207}N_{37}O_{35}S_2 = 3092.56$).

Example 3

15 **H-Cys-D-Lys-D-Lys-D-Trp-D-Lys-D-Met-D-Arg-D-Arg-D-Asn-D-Gln-D-Phe-D-Trp-D-Ile-D-Lys-D-Ile-D-Gln-D-Arg-NH₂**
Starting from Rink Amide AM resin (0.64 mmol/g; Novabiochem), the sequence H-Cys(Trt)-D-Lys(Boc)-D-Lys(Boc)-D-Trp-D-Lys(Boc)-D-Met-D-Arg(Pmc)-D-Arg(Pmc)-D-Asn (Trt)-D-Gln(Trt)-D-Phe-D-Trp-D-Ile-D-Lys(Boc)-D-Ile-D-Gln(Trt)-D-Arg(Pmc)-resin was assembled in quantitative yield. The peptidyl resin was 20 cleaved/deprotected (10 mL cleavage reagent/g; 2 h) and the crude peptide was isolated by precipitation from Et₂O, centrifugation/decantation and drying. An aliquot (100 mg) of this material was redissolved in 0.1 % aq TFA (2 mL) and filtered. The resulting solution was purified by preparative RP-HPLC (17.5 - 27.5 % MeCN 25 gradient) to afford, after vacuum centrifugation, pure title compound (36.4 mg). Anal. RP-HPLC: t_R = 16.3 min (17.5 - 27.5 % MeCN gradient; purity > 99 %, λ = 214 nm). DE MALDI-TOF MS: $[M + H]^+ = 2350.1$ ($C_{107}H_{174}N_{36}O_{20}S_2 = 2348.89$).

30 ***N*-{3-[3-(H-Cys-D-Lys-D-Lys-D-Trp-D-Lys-D-Met-D-Arg-D-Arg-D-Asn-D-Gln-D-Phe-D-Trp-D-Ile-D-Lys-D-Ile-D-Gln-D-Arg-NH₂)succinimido]benzoyl}doxorubicin**




N-[3-(Maleimido)benzoyl]doxorubicin (12.6 mg, 17 μ mol) and H-Cys-D-Lys-D-Lys-D-Trp-D-Lys-D-Met-D-Arg-D-Arg-D-Asn-D-Gln-D-Phe-D-Trp-D-Ile-D-Lys-D-Ile-D-Gln-D-Arg-NH₂ (20 mg, 8.5 μ mol) were dissolved in DMF (1 mL) and Et₃N (100 μ L) 5 was added. The mixture was stirred for 2 h, quenched by addition of AcOH (0.5 mL), diluted with water (0.5 mL) and filtered. The filtrate was purified by preparative RP-HPLC (20 - 40 % MeCN gradient) to afford the pure title compound as a red solid (6.3 mg). Anal. RP-HPLC: t_R = 16.3 min (0 - 60 % MeCN gradient; purity > 95 %). DE MALDI-TOF MS: [M + H]⁺ = 3092.7, (C₁₄₅H₂₀₈N₃₈O₃₄S₂ = 3091.57).

10

Example 4

2'-(Maleimidopropionoyl)paclitaxel




15

A mixture of paclitaxel (29.2 μ mol, 25mg), 3-maleimidopropionic acid (0.120 mmol, 20.3 mg) and DIC (66 μ mol, 10.3 μ L) in pyridine (1 mL) was stirred for 1 hr. The solvent was evaporated, the residue was treated with water and extracted with CH₂Cl₂. The organic phase was washed with water and brine and was dried over MgSO₄. The solvent was evaporated to dryness to afford 22.2 mg (76 %) colourless solid, which was recrystallised from EtOAc/hexane to provide the pure title compound. ¹H-NMR (300 MHz, CDCl₃) δ : 1.13, 1.22, 1.68, 1.91 (s, each 3H, CH₃), 2.23, 2.47 (s, each 3H, Ac-CH₃), 2.35 (m, 2H, H6), 2.78 (t, 4H, J = 5.40 Hz, CH₂), 2.84 (m, 2H, H14), 3.81 (m, 2H, CH₂), 3.87 (m, 1H, H3), 4.26 (m, 2H, H20), 4.44 (dd, 1H, J = 10.87, 4.25 Hz,

H7), 4.98 (d, 1H, J = 7.69 Hz, H5), 5.47 (d, 1H, J = 3.45 Hz, H2'), 5.68 (d, 1H, J = 7.09 Hz, H3'), 6.05 (dd, 1H, J = 9.28, 5.86 Hz, H2), 6.28 (s, 1H, H10), 6.18 (t, 1H, J = 8.77 Hz, H13), 6.49 (s, 2H, CH=CH), 8.16-7.34 (m, 15H, Ph). ^{13}C -NMR (75 MHz; CDCl₃) δ : 10.01, 15.20, 21.22, 22.54, 23.09, 27.18, 32.90, 33.71, 35.90, 43.54, 45.96, 5 52.86, 58.89, 72.18, 72.53, 74.86, 75.51, 76.02, 79.52, 81.42, 84.89, 126.94, 127.91, 128.74, 128.94, 129.14, 129.45, 129.59, 130.65, 132.39, 133.11, 133.85, 134.09, 134.46, 137.17, 143.25, 167.45, 168.01, 168.10, 169.77, 170.29, 171.10, 171.69, 204.24.

10 **2'-[Succinimidopropionoyl-(H-Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-OH)]paclitaxel**




A solution of 2'-(maleimidopropionoyl)paclitaxel (10 μmol , 10.05 mg) and H-Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-OH (10 μmol , 15 23.5 mg) in DMF (1 mL) was added Et₃N (1.39 μL , 10 μmol). The reaction mixture was stirred for 1 h. It was diluted with 0.1 % aq TFA (0.5 mL), filtered and purified by preparative RP-HPLC (10 – 70 % MeCN gradient). Pure title compound (20.5 mg, 62 %) was obtained as a colourless solid. Anal. RP-HPLC: $t_{\text{R}} = 17.4$ min (0 – 60 % MeCN gradient, purity > 97 %). DE MALDI-TOF MS: [M + H]⁺ = 3355.9 (C₁₆₁H₂₂₉N₃₇O₃₈S₂ 20 3354.90).

Example 5

25 **4(5)-carboxyfluorescein- β Ala-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-Gly-Cys-Gly-NH₂**

The peptide sequence was assembled on Rink Amide AM resin (0.65 mmol/g, 385 mg; Novabiochem) to afford H- β Ala-Arg(Pmc)-Gln(Trt)-Ile-Lys(Boc)-Ile-Trp-Phe-Gln(Trt)-Asn(Trt)-Arg(Pmc)-Arg(Pmc)-Met-Lys(Boc)-Trp-Lys(Boc)-Lys(Boc)-Gly-Cys(Trt)-Gly-resin (1.50 g, quant.). An aliquot of this peptidyl resin (450 mg, 75 μ mol) was stirred for 18 h in the dark with a solution of 4(5)-carboxyfluorescein (113 mg, 0.3 mmol), PyBOP (156 mg, 0.3 mmol), HOBr (41 mg, 0.3 mmol) and DIEA (78 μ L, 0.45 mmol) in DMF (4 mL). Resin was collected on a sinter and washed successively with DMF, CH_2Cl_2 and Et_2O . After drying, the resin was treated with cleavage reagent (5 mL, 1.5 h) in the dark. The product was isolated by precipitation with Et_2O and centrifugation (237 mg yellow powder). An aliquot (100 mg) was purified by preparative RP-HPLC (22.5 – 32.5 % MeCN gradient) to afford the pure title compound (36.9 mg) as a yellow film after isolation by vacuum centrifugation. Anal. RP-HPLC: t_R = 18.6 & 19.2 min (resolved 4- and 5-carboxyfluorescein geometric isomers) (22.5 – 32.5 % MeCN gradient, purity > 99 %, λ = 214 nm). DE MALDI-TOF MS: $[\text{M} + \text{H}]^+ = 2892.2$, $[\text{M} + \text{Na}]^+ = 2913.7$ ($\text{C}_{135}\text{H}_{195}\text{N}_{39}\text{O}_{29}\text{S}_2 = 2892.4$).

2'-[Succinimidopropionyl-(4(5)-carboxyfluorescein- β Ala-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-Gly-Cys-Gly-NH₂)]paclitaxel



20

To a solution of 2'-(maleimidopropionyl)paclitaxel (12.3 μ mol, 12.4 mg) and 4(5)-carboxyfluorescein- β Ala-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Gly-Cys-Gly-NH₂ (4.3 μ mol, 12.5 mg) in DMF (1 mL) was added Et₃N (1.8 μ L). The reaction mixture was stirred for 1 h. It was diluted with 0.1 % aq TFA (0.5 mL), filtered and purified by RP-HPLC (10 – 70 % MeCN gradient) to afford pure title compound (3.2 mg) as a colourless solid. Anal. RP-HPLC: t_R = 21.6 min (0 – 60


% MeCN gradient, purity > 97 %). DE MALDI-TOF MS: $[M + H]^+ = 3397.35$ ($C_{189}H_{251}N_{41}O_{46}S_2 = 3397.40$).

5 **Example 6**

H-Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-NH₂,

Starting from Rink Amide AM resin (0.69 mmol/g, Novabiochem), H-Cys(Trt)-
10 Arg(Pmc)-Gln(Trt)-Ile-Lys(Boc)-Ile-Trp-Phe-Gln(Trt)-Asn(Trt)-Arg(Pmc)-Arg(Pmc)-
Met-Lys(Boc)-Trp-Lys(Boc)-Lys(Boc)-resin was assembled. After deprotection (1.5
h), the crude peptide was obtained by precipitation from Et₂O,
centrifugation/decantation, and drying. Aliquots (total 472 mg) were purified by
preparative RP-HPLC (16.5 – 26.5 % MeCN gradient) to afford the pure title
15 compound (109.9 mg). Anal. RP-HPLC: $t_R = 16.0$ min (17.5 – 27.5 % MeCN gradient,
purity > 99 %, $\lambda = 214$ nm). DE MALDI-TOF MS: $[M + H]^+ = 2349.3$
($C_{107}H_{174}N_{36}O_{20}S_2 = 2348.89$).

20 **2'-[Succinimidopropionoyl-(H-Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-
Arg-Met-Lys-Trp-Lys-Lys-NH₂)]paclitaxel**



To a solution of 2'-(maleimidopropionoyl)paclitaxel (9 μ mol, 9 mg) and H-Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-NH₂ (9 μ mol, 20.9 mg) in DMF (1 mL) was added Et₃N (1.8 μ L). The mixture was stirred for 1 h, diluted
25 with 0.1 % aq TFA (0.5 mL), filtered and purified by preparative RP-HPLC (10 – 70 % MeCN gradient). The pure title compound (15.9 mg, 53 %) was obtained as a

colourless solid. Anal. RP-HPLC: $t_R = 18.5$ min (0 - 60% MeCN gradient, purity > 97 %). DE MALDI-TOF MS: $[M + H]^+ = 3353.6$ ($C_{161}H_{230}N_{38}O_{37}S_2 = 3353.91$).


5

Example 7

H-Cys- β Ala-Arg-Arg-Met-Lys-Trp-Lys-Lys-NH₂

10 Starting from Rink Amide AM resin (0.69 mmol/g, Novabiochem), H-Cys(Trt)- β Ala-Arg(Pmc)-Arg(Pmc)-Met-Lys(Boc)-Trp-Lys(Boc)-Lys(Boc)-resin was assembled. After deprotection (1.5 h), the crude peptide was obtained by precipitation from Et₂O, centrifugation/decantation, and drying. Aliquots (total 246 mg) were purified by preparative RP-HPLC (6.5 – 16.5 % MeCN gradient) to afford the pure title compound 15 (106.4 mg). Anal. RP-HPLC: $t_R = 15.8$ min (6.5 – 16.5 % MeCN gradient, purity > 95 %, $\lambda = 214$ nm). DE MALDI-TOF MS: $[M + H]^+ = 1205.4$ ($C_{52}H_{92}N_{20}O_{9}S_2 = 1205.55$).

20 **2'-[Succinimidopropionoyl-(H-Cys- β Ala-Arg-Arg-Met-Lys-Trp-Lys-Lys-NH₂)]paclitaxel**



To a solution of 2'-(maleimidopropionoyl)paclitaxel (17 μ mol, 17.4 mg) and H-Cys- β Ala-Arg-Arg-Met-Lys-Trp-Lys-Lys-NH₂ (15 μ mol, 18.1 mg) in DMF (1 mL) was added Et₃N (2.0 μ L). The mixture was stirred for 1h, filtered and purified by 25 preparative RP-HPLC (10 – 70 % MeCN gradient). The pure title compound (9.4 mg) was obtained as a colourless solid. Anal. RP-HPLC: $t_R = 17.2$ min (0 – 60 % MeCN


gradient, purity > 97 %). DE MALDI-TOF MS: $[M + H]^+ = 2211.7$ ($C_{106}H_{148}N_{22}O_{26}S_2$ = 2210.57).

5

Example 8

10


2'-Methoxyacetyl-7-(maleimidopropionoyl)paclitaxel



A solution of paclitaxel (29 μ mol, 25 mg), methoxyacetic acid *N*-hydroxysuccinimidyl ester (0.176 mmol, 32.8 mg) and of DIEA (0.176 mmol, 30.6 μ L) in CH_2Cl_2 (1 mL) 15 was heated under reflux for 4 h. Methanol (1.6 μ L) was added. After stirring for 10 min, the reaction mixture was washed with 0.1 M aq HCl, water, brine, and was dried on $MgSO_4$. The solvent was evaporated *in vacuo* to afford 2'- (methoxyacetyl)paclitaxel as a white solid (24.8 mg, 91 %). This material (30 μ mol), together with 3-maleimidopropionic acid, DIC (14.1 μ L, 90 mmol) and DMAP (20 μ mol, 2.6 mg) was dissolved in CH_2Cl_2 (2.5 mL) and the mixture was stirred for 40 min. It was washed with water and dried on $MgSO_4$. The solvent was removed *in vacuo* to afford a light-yellow solid. This was redissolved in DMF/MeOH, filtered and purified by preparative RP-HPLC (20 – 70 % MeCN gradient) to afford the pure title compounds as a colourless solid (24.4 mg, 76 %). Anal. RP-HPLC: $t_R = 21.8$ min (10 – 25 70 % MeCN gradient, purity > 98 %). 1H -NMR (300 MHz, $CDCl_3$) δ : 1.15, 1.20, 1.79, 1.96 (s, each 3H, CH_3 x 4), 2.20, 2.45 (s, each 3H, Ac- CH_3 x 2), 2.34 (m, 2H, H6), 2.63 (m, 4H, H14, CH_2), 3.40 (s, 3H, OCH_3), 3.73-3.94 (m, 3H, CH_2 , H3), 4.16-4.21


(m, 2H, H20), 4.97 (d, 1H, J = 8.06 Hz, H5), 5.54-5.69 (m, 3H, H7, H2, H3'), 5.98 (m, 1H, H2'), 6.22 (s, 1H, H10), 6.24 (m, 1H, H13), 6.68 (s, 2H, CH=CH), 7.12-8.13 (m, 15H, Ph).

5 **2'-Methoxyacetyl-7-[succinimidopropionoyl-(H-Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-OH)]paclitaxel**



To a solution of 2'-methoxyacetyl-7-(maleimidopropionoyl)paclitaxel (11 μ mol, 12.3 mg) and H-Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-
10 Lys-OH (11 μ mol, 26.8 mg) in DMF (1 mL) was added Et₃N (1.58 μ L, 11 μ mol). The mixture was stirred for 2 h, diluted with 0.1 % aq TFA (0.5 mL) and purified by preparative RP-HPLC (10 – 70 % MeCN gradient). The pure title compound was obtained as a colourless solid (15.5 mg, 40 %). Anal. RP-HPLC: t_R = 15.1 min (10 – 70 % MeCN gradient, purity > 97 %). DE MALDI-TOF MS: [M + H]⁺ = 3425.99
15 ($C_{164}H_{233}N_{37}O_{40}S_2$ = 3424.96).

7-[Succinimidopropionoyl-(H-Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-OH)]paclitaxel




To 2'-methoxyacetyl-7-[succinimidopropionoyl-(H-Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-OH)]paclitaxel (35 μ mol, 11.9 mg) in MeOH (1 mL) was added ethanolamine (0.21 μ L). The mixture was stirred for 1 h, diluted

5 with 0.1 % aq TFA (0.5 mL), filtered and purified by preparative RP-HPLC (10 – 70 % MeCN gradient). The pure title compound was obtained as a colourless solid (5.6 mg, 48 %). Anal. RP-HPLC: t_R = 14.3 min (10 – 70 % MeCN gradient, purity > 97 %). DE MALDI-TOF MS: $[M + H]^+ = 3355.7$, ($C_{161}H_{229}N_{37}O_{38}S_2 = 3354.90$).

10

Example 9

2'-(*p*-Methoxytrityl)paclitaxel




15 A solution of paclitaxel (0.632 mmol, 540 mg) and *p*-methoxytrityl chloride (10 mol eq) in CH_2Cl_2 (10 mL) was treated with pyridine (1.3 mL) under N_2 . After stirring of the mixture for 22 h, solvents were evaporated in *vacuo*. The residue was redissolved in EtOAc, washed with water and brine and was dried on $MgSO_4$. The solvent was evaporated to afford a light yellow solid which was purified by flash chromatography (8:9 EtOAc/PE) to afford the pure title compound in a quantitative yield.

20


Recrystallisation from EtOAc/CH₂Cl₂ gave light yellow crystals. ¹H-NMR (300 MHz, CDCl₃) δ: 1.08, 1.15, 1.51, 1.65, (s, each 3H, CH₃×4), 1.90 (m, 1H, H6), 2.25, 2.29 (s, each 3H, Ac-CH₃×2), 2.55 (m, 1H, H6), 2.54 (m, 2H, H14), 3.75 (s, 3H, OCH₃), 3.66 (m, 1H, H3), 4.20 (m, 2H, H20), 4.40 (m, 1H, H7), 4.62 (m, 1H, H2'), 4.94 (d, 1H, *J*= 8.06 Hz, H5), 5.61 (m, 1H, H2), 5.70 (m, 2H, H13, H3'), 6.19 (s, 1H, H10), 6.72-8.08 (m, 29H, Ph).

2'-(*p*-Methoxytrityl)-7-(maleimidopropionoyl)paclitaxel



10 2'-(*p*-Methoxytrityl)paclitaxel (35 μmol, 38.4 mg) and pyridine (125 μL) were dissolved in CH₂Cl₂ (2 mL). A solution of 3-maleimidopropionic acid (1.48 mmol, 250.5 mg), DIC (0.80 mmol, 101.5 mg) and DMAP (10 mg) in CH₂Cl₂ (2 mL) was added and the mixture was stirred for 1 h. The solvent was evaporated and the residue was partitioned between water and CH₂Cl₂. The organic layer was washed with water, brine and was dried on MgSO₄. The solvent was removed and the residue was purified by Chromatotron® centrifugal thin-layer chromatography (5:4 EtOAc/PE). Recrystallisation from EtOAc/CH₂Cl₂ afforded the title compound as a colourless solid (22 mg, 49 %). ¹H-NMR (300 MHz, CDCl₃) δ: 1.18, 1.12, 1.76, 1.96 (s, each 3H, CH₃×4), 2.17, 2.26 (s, each 3H, Ac-CH₃×2), 2.10, 2.34 (m, 2H, H6), 2.62 (m, 4H, H14, CH₂-Mim), 3.75 (s, 3H, OCH₃), 3.73-3.79 (m, 3H, CH₂-Mim, H3), 4.06 (m, 2H, H20), 4.61 (d, 1H, *J*= 3.47 Hz, H2'), 4.76 (d, 1H, *J*= 9.52 Hz, H5), 5.53 (m, 1H, H7), 5.60 (d, 1H, *J*= 6.98 Hz, H3'), 5.71 (m, 1H, H2), 6.14 (s, 1H, H10), 6.60 (m, 3H, H13, CH=CH), 6.75-7.79 (m, 29H, Ph).


25 **7-(Maleimidopropionoyl)paclitaxel**



A solution of 2'-(*p*-methoxytrityl)-7-(maleimidopropionoyl)paclitaxel (17 μ mol, 22 mg), anisole (1.72 mmol, 186.4 mg) and chloroacetic acid (0.172 mmol, 16.3 mg) in CH_2Cl_2 (10 mL) was stirred for 4 h. The reaction mixture was washed with 1 % aq 5 Na_2CO_3 , water, brine and was dried on MgSO_4 . The solvent was evaporated to dryness and the residue was purified by Chromatotron® centrifugal thin-layer chromatography (1:1 EtOAc/PE) to afford pure title compound as a white solid (24 mg), which was recrystallised from EtOAc/ CH_2Cl_2 . $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ : 1.15, 1.18, 1.20, 1.76, 2.04 (s, each 3H, CH_3 x 4), 2.18, 2.37 (s, each 3H, Ac- CH_3 x 2), 10 2.34 (m, 2H, H6), 2.64 (m, 4H, H14, CH_2), 3.78-3.91 (m, 3H, CH_2 , H3), 4.12 (m, 2H, H20), 4.71 (d, 1H, J = 3.25 Hz, H2'), 4.94 (d, 1H, J = 8.17 Hz, H5), 5.54 (dd, 1H, J = 10.46, 7.21 Hz, H7), 5.66 (d, 1H, J = 6.88 Hz, H3'), 5.80 (dd, 1H, J = 8.92, 2.42 Hz, H2), 6.15 (m, 1H, H13), 6.18 (s, 1H, H10), 6.68 (s, 2H, $\text{CH}=\text{CH}$), 7.10-8.12 (m, 15H, Ph).

15

7-[Succinimidopropionoyl-(H-Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-OH)]paclitaxel




To a solution of 7-(maleimidopropionoyl)paclitaxel (4.8 μ mol, 4.8 mg) and H-Cys-20 Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-OH (4.8 μ mol,

11.2 mg) in DMF (1 mL) was added Et₃N (0.67 μ L). The mixture was stirred for 30 min, filtered and purified by preparative RP-HPLC (10 – 70 % MeCN gradient) to afford the pure title compound as a colourless solid (8.6 mg, 54 %). Anal. RP-HPLC: t_R = 14.3 min (10 – 70 % MeCN gradient, purity > 97 %). DE MALDI-TOF MS: 5 [M+H]⁺ = 3355.0 (C₁₆₁H₂₂₉N₃₇O₃₈S₂ = 3354.90).


Example 10

10 4-(Maleimidopropionoyl)podophyllotoxin



A solution of podophyllotoxin (60 μ mol, 25.6 mg), 3-maleimidopropionic acid (0.31 mmol, 52.4 mg), DIC (0.17 mmol, 21.5 mg) and DMAP (80 μ mol, 10 mg) in CH₂Cl₂ (2 mL) was stirred for 1 h. The solvent was evaporated *in vacuo* and the residue was 15 redissolved in DMF/MeOH (1 mL) and purified by preparative RP-HPLC (20 – 70 % MeCN gradient) to afford the pure title compound as a colourless solid (7.3 mg). Anal. RP-HPLC: t_R = 20.1 min (0 – 60 % MeCN gradient, purity > 95 %). ¹H-NMR (300 MHz, CDCl₃) δ : 2.66-2.71 (t, *J* = 6.3 Hz, 2H, CH₂), 2.82-2.84 (m, 2H, H2 and H3), 3.69 (s, 6H, OCH₃×2), 3.75 (s, 3H, OCH₃), 3.83 (t, *J* = 6.3 Hz, 2H, CH₂), 4.12 (t, *J* = 19.92 Hz, 1H, H11), 4.31 (m, 1H, H11), 4.53 (d, *J* = 11.4 Hz, 1H, H1), 5.80 (d, *J* = 8.7 Hz, 1H, H4), 5.92 (dd, *J* = 5.49, 1.17 Hz, 2H, OCH₂O), 6.32 (s, 2H, H2'6'), 6.47 (s, 1H, H8), 6.66 (s, 2H, CH=CH), 6.74 (s, 1H, H5).

25 4-[Succinimidopropionoyl-(H-Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-OH)]podophyllotoxin




To a solution of 4-(maleimidopropionyl)podophyllotoxin (8 μ mol, 5 mg) and H-Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-OH (7.7 μ mol, 18 mg) in 1 DMF (1 mL) was added Et₃N (1.06 μ L, 11.4 μ mol). The mixture was 5 stirred for 30 min, diluted with 0.1 % aq TFA (0.5 mL), filtered and purified by preparative RP-HPLC (10 – 60 % MeCN gradient) to afford the pure title compound as a colourless solid (7.8 mg, 35 %). Anal. RP-HPLC: t_R = 12.8 min (0 - 60 % MeCN gradient, purity > 97 %). DE MALDI-TOF MS: $[M + H]^+$ = 2915.34 (C₁₃₆H₂₀₀N₃₆O₃₂S₂ = 2915.40).

10

Example 11

Biotinamidocaproyl- β Ala-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-15 Lys-Trp-Lys-Lys-Gly-Cys-Gly-NH₂,
 H- β Ala-Arg(Pmc)-Gln(Trt)-Ile-Lys(Boc)-Ile-Trp-Phe-Gln(Trt)-Asn(Trt)-Arg(Pmc)-
 Arg(Pmc)-Met-Lys(Boc)-Trp-Lys(Boc)-Lys(Boc)-Gly-Cys(Trt)-Gly-resin (450 mg, 75
 μ mol) was stirred with a solution of biotinamidocaproic acid *N*-hydroxysuccinimidyl
 ester (136 mg, 0.3 mmol), HOBr (41 mg, 0.3 mmol) and DIEA (105 μ L, 0.6 mmol) in
 20 DMF (3 mL) for 18 h. The peptidyl resin was collected on a sinter and washed
 successively with DMF, CH₂Cl₂, and Et₂O. After drying *in vacuo*, it was treated with
 cleavage reagent (5 mL, 1.5 h). The biotinylated peptide was isolated by precipitation
 with Et₂O and centrifugation (244 mg product). An aliquot (120 mg) was purified by
 preparative RP-HPLC (20 – 30 % MeCN gradient) to afford the pure title compound as
 25 a colourless solid (63.8 mg). Anal. RP-HPLC: t_R = 16.7 min (20 – 30 % MeCN
 gradient, purity > 99 %, λ = 214 nm). DE MALDI-TOF MS: $[M + H]^+$ = 2874.3, $[2M
 + H]^+$ = 5738.7, $[M + 2H]^{2+}$ = 1437.8 (C₁₃₀H₂₁₀N₄₂O₂₆S₃ = 2873.52).


4-[Succinimidopropionoyl-(biotinamidocaproyl- β Ala-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-Gly-Cys-Gly-NH₂)]podophyllotoxin



5 To a solution of 4-(maleimidopropionoyl)podophyllotoxin (7 μ mol, 4 mg) and biotinamidocaproyl- β Ala-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-Gly-Cys-Gly-NH₂ (7 μ mol, 20.7 mg) in DMF (0.5 mL) was added Et₃N (1.0 μ L). The mixture was stirred for 1 h, diluted with 0.1 % aq TFA (0.5 mL), filtered and purified by preparative RP-HPLC (10 – 70 % MeCN gradient). The pure title 10 compound was obtained as a colourless solid (2.2 mg). Anal. RP-HPLC: t_R = 17.2 min (0 – 60 % MeCN gradient, purity > 97 %). DE MALDI-TOF MS: [M + H]⁺ = 3438.9 ($C_{159}H_{237}N_{43}O_{37}S_2$ = 3439.05).

15 **Example 12**

4-[Succinimidopropionoyl-(H-Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-NH₂)]podophyllotoxin



20 To a solution of 4-(maleimidopropionoyl)podophyllotoxin (20 μ mol, 12.2 mg) and H-Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-NH₂ (15 μ mol, 34.7 mg) in DMF (1.5 mL) was added Et₃N (5 μ L). The mixture was stirred for 40 min and purified by preparative RP-HPLC (0 – 60 % MeCN gradient) to afford the

pure title compound as a colourless solid (30.1 mg, 69 %). Anal. RP-HPLC: $t_R = 15.8$ min (0 – 60 % MeCN gradient, purity > 98 %). DE MALDI-TOF MS: $[M + H]^+ = 2914.4$ ($C_{136}H_{201}N_{37}O_{31}S_2 = 2914.41$).


5

Example 13

H-Cys-D-Arg-D-Gln-D-Ile-D-Lys-D-Ile-D-Trp-D-Phe-D-Gln-D-Asn-D-Arg-D-Arg-D-Nle-D-Lys-D-Trp-D-Lys-D-Lys-NH₂

10 Starting from Rink Amide AM resin (0.69 mmol/g, Novabiochem), H-Cys(Trt)-D-Arg(Pmc)-D-Gln(Trt)-D-Ile-D-Lys(Boc)-D-Ile-D-Trp-D-Phe-D-Gln(Trt)-D-Asn(Trt)-D-Arg(Pmc)-D-Arg(Pmc)-D-Nle-D-Lys(Boc)-D-Trp-D-Lys(Boc)-D-Lys(Boc)-resin was assembled. After deprotection (1.5 h), the crude peptide was obtained by precipitation from Et₂O, centrifugation/decantation, and drying. Aliquots (total 246 mg) were purified by preparative RP-HPLC (17.5 – 27.5 % MeCN gradient) to afford the pure title compound (45.9 mg). Anal. RP-HPLC: $t_R = 16.9$ min (17.5 – 27.5 % MeCN gradient, purity > 99 %, $\lambda = 214$ nm). DE MALDI-TOF MS: $[M + H]^+ = 2330.3$ ($C_{108}H_{176}N_{36}O_{20}S = 2330.85$).

15 20 **4-[Succinimidopropionoyl-(H-Cys-D-Arg-D-Gln-D-Ile-D-Lys-D-Ile-D-Trp-D-Phe-D-Gln-D-Asn-D-Arg-D-Arg-D-Nle-D-Lys-D-Trp-D-Lys-D-Lys-NH₂)]podophyllotoxin**



25 To a solution of 4-(maleimidopropionoyl)podophyllotoxin (11 μ mol, 6.2 mg) and H-Cys-D-Arg-D-Gln-D-Ile-D-Lys-D-Ile-D-Trp-D-Phe-D-Gln-D-Asn-D-Arg-D-Arg-D-Nle-D-Lys-D-Trp-D-Lys-D-Lys-NH₂ (7 μ mol, 17 mg) in DMF (1 mL) was added Et₃N (1.4 μ L). The mixture was stirred for 30 min, filtered and purified by preparative RP-HPLC (0 – 60 % MeCN gradient) to afford the pure title compound as a colourless


solid (10.5 mg, 52 %). Anal. RP-HPLC: $t_R = 15.8$ min (0 – 60 % MeCN gradient, purity > 98 %). DE MALDI-TOF MS: $[M + H]^+ = 2895.66$ ($C_{137}H_{203}N_{37}O_{31}S_2 = 2896.37$).

5

Example 14

4-[Succinimidopropionoyl-(H-Cys- β Ala-Arg-Arg-Met-Lys-Trp-Lys-Lys-NH₂)]podophyllotoxin

10



15

To a solution of 4-(maleimidopropionoyl)podophyllotoxin (17.7 μ mol, 10 mg) and H-Cys- β Ala-Arg-Arg-Met-Lys-Trp-Lys-Lys-NH₂ (25 μ mol, 30.4 mg) in DMF (1.5 mL) was added Et₃N (3.5 μ L). The mixture was stirred for 40 min, filtered and purified by preparative RP-HPLC (0 – 60 % MeCN gradient). The pure title compound was obtained as a colourless solid (17.8 mg, 57 %). Anal. RP-HPLC: $t_R = 14.8$ min (0 – 60 % MeCN gradient, purity > 98 %). DE MALDI-TOF MS: $[M + H]^+ = 1772.3$ ($C_{81}H_{119}N_{21}O_{20}S_2 = 1771.07$).

20

Example 15


H-Cys- β Ala-D-Arg-D-Arg-D-Met-D-Lys-D-Trp-D-Lys-D-Lys-NH₂

Starting from Rink Amide AM resin (0.69 mmol/g, Novabiochem), H-Cys(Trt)- β Ala-D-Arg(Pmc)-D-Arg(Pmc)-D-Met-D-Lys(Boc)-D-Trp-D-Lys(Boc)-D-Lys(Boc)-resin was assembled. After deprotection (1.5 h), the crude peptide was obtained by precipitation from Et₂O, centrifugation/decantation, and drying. Aliquots (total 237

mg) were purified by preparative RP-HPLC (8 – 18 % MeCN gradient) to afford the pure title compound (66 mg). Anal. RP-HPLC: t_R = 12.9 min (9 – 19 % MeCN gradient, purity > 99 %, λ = 214 nm). DE MALDI-TOF MS: $[M + H]^+$ = 1207.2 ($C_{52}H_{92}N_{20}O_{9}S_2$ = 1205.55).

5

4-[Succinimidopropionoyl-(H-Cys- β -Ala-D-Arg-D-Arg-D-Met-D-Lys-D-Trp-D-Lys-D-Lys-NH₂)]podophyllotoxin




To a solution of 4-(maleimidopropionoyl)podophyllotoxin (18.9 μ mol, 10.7 mg) and H-Cys- β Ala-D-Arg-D-Arg-D-Met-D-Lys-D-Trp-D-Lys-D-Lys-NH₂ (28 μ mol, 33.8 mg) in DMF (1.5 mL) was added Et₃N (1.5 μ L). The mixture was stirred for 40 min, filtered and purified by preparative RP-HPLC (0 – 60 % MeCN gradient). The pure title compound was obtained as a colourless solid (6.9 mg, 21 %). Anal. RP-HPLC: t_R = 14.8 min (0 – 60 % MeCN gradient, purity > 98%). DE MALDI-TOF MS: $[M + H]^+$ = 1771.5 ($C_{81}H_{119}N_{21}O_{20}S_2$ = 1771.07).

20

Example 16


25 **4'--(Maleimidopropionoyl)epipodophyllotoxin**



A solution of 4'-demethylepipodophyllotoxin (12 mmol, 5 mg), 3-maleimidopropionic acid (50 μ mol, 12.2 mg) and DIC (28 μ mol, 3.47 mg) in pyridine (1 mL) was stirred for 30 min. MeOH (0.5 mL) was added and the mixture was 5 purified by preparative RP-HPLC (0 – 60 % MeCN gradient) to afford the pure title compound as a colourless solid (4.2 mg, 62 %). Anal. RP-HPLC: t_R = 17.6 min (0 – 60 % MeCN gradient, purity > 95 %). 1 H-NMR (300 MHz, CDCl₃) δ : 2.84 (m, 1H, H3), 2.99 (t, J = 7.44 Hz, 2H, CH₂-Mim), 3.32 (dd, J = 14.04, 5.07 Hz, 1H, H2), 3.69 (s, 6H, OCH₃×2), 3.95 (t, J = 7.44 Hz, 2H, CH₂-Mim), 4.39 (dd, J = 8.13, 4.28 Hz, 2H, 10 H11), 4.66 (d, J = 5.00 Hz, 1H, H1), 4.89 (d, J = 3.32 Hz, 1H, H4), 6.01 (d, J = 6.42 Hz, 2H, OCH₂O), 6.32 (s, 2H, H2'6'), 6.57 (s, 1H, H8), 6.74 (s, 2H, CH=CH), 6.90 (s, 1H, H5). 13 C-NMR (75 MHz, CDCl₃) δ : 28.64, 31.02, 32.55, 37.33, 39.53, 42.99, 55.15, 65.78, 66.56, 100.65, 106.54, 107.97, 109.65, 130.68, 130.92, 133.21, 136.96, 146.62, 147.61, 150.39, 167.36, 169.30, 173.89.

15

4'-[Succinimidopropionoyl-(H-Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-OH)]epipodophyllotoxin




To a solution of 4'-(maleimidopropionoyl)epipodophyllotoxin (2.3 μ mol, 1.3 mg) and 20 H-Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-OH (2.3 μ mol, 5.4 mg) in DMF (0.5 mL) was added Et₃N (0.21 μ L, 2.3 μ mol). The mixture

was stirred for 40 min, diluted with 0.1 % aq TFA (1 mL), filtered and purified by preparative RP-HPLC (0 – 60 % MeCN gradient) to afford the pure title compound as a colourless solid (3.2 mg, 48 %). Anal. RP-HPLC: t_R = 14.6 min (0 – 60 % MeCN gradient, purity > 98 %). DE MALDI-TOF MS: $[M + H]^+$ = 2902.2 ($C_{135}H_{198}N_{36}O_{32}S_2$ = 2901.37).

Example 17

10 **4'-[Succinimidopropionoyl-(H-Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-NH₂)]epipodophyllotoxin**




To a solution of 4'-(maleimidopropionoyl)epipodophyllotoxin (7 μ mol, 4 mg) and H-Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-NH₂ (6 μ mol, 15 mg) in DMF (0.5 mL) was added Et₃N (1 μ L). The mixture was stirred for 40 min and was purified by preparative RP-HPLC (0 – 60 % MeCN gradient) to afford the pure title compound as a colourless solid (14.1 mg, 81 %). Anal. RP-HPLC: t_R = 19.7 min (0 – 60 % MeCN gradient, purity > 98 %). DE MALDI-TOF MS: $[M + H]^+$ = 2900.4, $C_{135}H_{199}N_{37}O_{31}S_2$ = 2900.39.

20

Example 18

15 **4'-[Succinimidopropionoyl-(H-Cys- β Ala-Arg-Arg-Met-Lys-Trp-Lys-Lys-NH₂)]epipodophyllotoxin**




To a solution of 4'-(maleimidopropionoyl)epipodophyllotoxin (14 μ mol, 7.9 mg) and H-Cys- β Ala-Arg-Arg-Met-Lys-Trp-Lys-Lys-NH₂ (26 μ mol, 31.5 mg) in DMF (1 mL) was added Et₃N (1.9 μ L). After stirring for 40 min, the mixture was purified by 5 preparative RP-HPLC (0 – 60 % gradient) to afford the pure title compound as a colourless solid (15.8 mg, 63 %). Anal. RP-HPLC: t_R = 13.3 min (0 – 60 % MeCN gradient, purity > 98 %). DE MALDI-TOF MS: $[M + H]^+ = 1757.2$ ($C_{80}H_{117}N_{21}O_{20}S_2 = 1757.05$).

10

Example 19


4'-(Chloroacetyl)epipodophyllotoxin



15 To a stirring solution of 4'-demethylepipodophyllotoxin (0.50 mmol, 200 mg) and pyridine (40 μ L) in CH₂Cl₂ (2 mL) at 0 °C, chloroacetyl chloride (0.50 mmol, 56.5 mg) was added dropwise. By anal. RP-HPLC about 60 % of 4'-demethylepipodophyllotoxin starting material was consumed after 1 hr stirring at 0 °C. The reaction mixture was poured into chilled water and this was extracted with 20 CH₂Cl₂. The organic layer was washed with water, brine and was dried on MgSO₄. The solvent was evaporated *in vacuo* and the residue was purified by flash


chromatography (5:4 – 3:2 EtOAc/PE). The pure title compound was obtained after recrystallisation from EtOAc/PE as a colourless solid (81.5 mg, 34 %). ¹H-NMR (300 MHz, CDCl₃) δ: 2.78 (m, 1H, H3), 3.25 (dd, *J* = 14.12, 5.07 Hz, 1H, H2), 3.68 (s, 6H, OCH₃×2), 4.30 (m, 2H, H11), 4.35 (s, 2H, CH₂Cl), 4.57 (d, *J* = 5.12 Hz, 1H, H1), 4.83 5 (d, *J* = 3.37 Hz, H4), 5.96 (d, *J* = 4.10 Hz, 2H, OCH₂O), 6.32 (s, 2H, H2'6'), 6.50 (s, 1H, H8), 6.87 (s, 1H, H5).

4'-Chloroacetyl-4-(maleimidopropionoyl)epipodophyllotoxin



10 A solution of 4'-(chloroacetyl)epipodophyllotoxin (0.17 mmol, 81.5 mg), 3-maleimidopropionic acid (0.68 mmol, 115.6 mg), DIC (0.376 mmol, 47.5 mg), DMAP (73 μmol, 9 mg) and pyridine (20 μL) in CH₂Cl₂ (2 mL) was stirred for 1 h. The solvent was evaporated to dryness. The resulting light-yellow solid was redissolved in DMF (1 mL) and was purified by preparative RP-HPLC (30 – 70 % MeCN gradient) 15 to afford the pure title compound as a colourless solid (54.3 mg, 51 %). Anal. RP-HPLC: *t*_R = 22.0 min (0 – 60 % MeCN gradient, purity > 97 %). ¹H-NMR (300 MHz, CDCl₃) δ: 2.71 (t, 2H, *J* = 6.80 Hz, CH₂-Mim), 2.98 (m, 1H, H3), 3.25 (dd, *J* = 14.20, 5.13 Hz, 1H, H2), 3.69 (s, 6H, OCH₃×2), 3.87 (t, *J* = 6.83 Hz, 2H, CH₂-Mim), 3.88 (m, 1H, H11), 4.33 (s, 2H, CH₂Cl), 4.35 (m, 1H, H11), 4.70 (d, *J* = 5.10 Hz, 1H, H1), 6.01 20 (d, *J* = 4.23 Hz, 2H, OCH₂O), 6.13 (d, *J* = 3.50 Hz, 1H, H4), 6.31 (s, 2H, H2'6'), 6.56 (s, 1H, H8), 6.71 (s, 2H, CH=CH), 6.92 (s, 1H, H5).


4'-Chloroacetyl-4-[succinimidopropionoyl-(H-Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-OH)epipodophyllotoxin



To a solution of 4'-chloroacetyl-4-(maleimidopropionoyl)epipodophyllotoxin (6.8 μ mol, 43 mg) and H-Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-OH (10 μ mol, 25.4 mg) in DMF (1.5 mL) was added Et₃N (2.5 μ L). The

5 mixture was stirred for 30 min and was purified by preparative RP-HPLC (10 – 70 % MeCN gradient) to afford the pure title compound as a colourless solid (22 mg, 67 %). Anal. RP-HPLC: t_R = 16.7 min (0 – 60 % MeCN gradient, purity > 99 %). DE MALDI-TOF MS: [M + H]⁺ = 2978.3 (C₁₃₇H₁₉₉ClN₃₆O₃₃S₂ = 2977.85).

10 **4'-Demethyl-4-[succinimidopropionoyl-(H-Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Met-Lys-Trp-Lys-Lys-OH)]epipodophyllotoxin**



A solution of 4'-chloroacetyl-4-[succinimidopropionoyl-(H-Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Met-Lys-Trp-Lys-Lys-OH)]epipodophyllotoxin (5.5 μ mol, 16.4 mg) in DMF (1 mL) and water (0.5 mL) at 0 °C was treated with conc. aq NH₃

15 solution (20 μ L). After 2 min the reaction mixture was acidified by addition of 5 % aq AcOH (0.1 mL). It was purified by preparative RP-HPLC (0 - 60% MeCN gradient) to afford the pure title compound as a colourless solid (11.4 mg, 73 %). Anal. RP-HPLC: t_R = 14.9 min (0 - 60% MeCN gradient, purity > 99 %). DE MALDI-TOF MS: [M + H]⁺ = 2902.2 (C₁₃₅H₁₉₈N₃₆O₃₂S₂ = 2901.37).


Example 20

G2-(Maleimidopropionoyl)etoposide, G3-(maleimidopropionoyl)etoposide, and 4'-(maleimidopropionoyl)etoposide

A solution of etoposide (37.4 μ mol, 22 mg), 3-maleimidopropionic acid (78 μ mol, 13.2 mg) and DIC (39.6 μ mol, 5 mg) in a mixture of CH_2Cl_2 /pyridine (2:0.15) was 5 stirred for 30 min. The solvents were removed *in vacuo*. The resulting light-yellow solid was dissolved in MeOH (1.5 mL) and was purified by preparative RP-HPLC (10 – 70 % MeCN gradient) to afford G2-(maleimidopropionoyl)etoposide (3.4 mg), G3-(maleimidopropionoyl)etoposide (2.4 mg) and 4'-(maleimidopropionoyl)etoposide (7.7 mg) as colourless solids (total yield 48 %).


10

G2-(Maleimidopropionoyl)etoposide




Anal. RP-HPLC: $t_{\text{R}} = 16.7$ min (0 – 60 % MeCN gradient, purity > 99 %). $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ : 1.39 (d, $J = 4.99$ Hz, 3H, CH_3), 2.39 (t, $J = 7.30$ Hz, 2H, CH_2 -Mim), 2.87 (m, 1H, H3), 3.14 (dd, $J = 14.20, 5.09$ Hz, 1H, H2), 3.39 (m, 2H, G4,5), 15 3.63 (m, 2H, G2,6), 3.72 (m, 2H, CH_2 -Mim), 3.76 (s, 6H, $\text{OCH}_3 \times 2$), 3.84 (t, $J = 8.9$ Hz, 1H, G3), 4.19 (m, 2H, H11, G6), 4.38 (m, 1H, H11), 4.60 (d, $J = 4.10$ Hz, 1H, H4), 4.74-4.84 (m, 2H, H1, G6). 6.00 (d, $J = 5.10$ Hz, 2H, OCH_2O), 6.24 (s, 2H, H2'6'), 17 6.54 (s, 1H, H8), 6.70 (s, 2H, $\text{CH}=\text{CH}$), 6.75 (s, 1H, H5). $^{13}\text{C-NMR}$ (75 MHz, CDCl_3) δ : 20.66, 33.48, 33.95, 37.86, 41.46, 44.00, 56.87, 66.75, 68.07, 68.34, 72.15, 74.61, 20 75.26, 80.24, 100.29, 100.434, 102.07, 108.33, 109.00, 111.33, 128.75, 130.90, 133.40, 134.50, 134.66, 146.80, 147.27, 149.09, 169.94, 170.78, 175.08.

G3-(Maleimidopropionoyl)etoposide



Anal. RP-HPLC: t_R = 18.4 min (0 – 60 % MeCN gradient, purity > 99 %). $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ : 1.33 (d, J = 5.0 Hz, 3H, CH_3), 2.74 (t, J = 7.35 Hz, 2H, CH_2 -Mim), 2.91 (m, 1H, H3), 3.28 (dd, J = 14.01, 5.26 Hz, 1H, H2), 3.38 (m, 2H, G4,5), 5 3.54 (m, 2H, G2,6), 3.87 (m, 2H, CH_2 -Mim), 3.76 (s, 6H, OCH_3 x2), 4.16-4.26 (m, 2H, H11, G3), 4.42 (t, J = 8.98 Hz, 1H), 4.61 (d, J = 5.09 Hz, 1H, H1), 4.68 (m, 1H, G1), 4.91 (d, J = 3.34 Hz, H4), 5.13 (m, 1H, G3). 6.00 (d, J = 11.25 Hz, 2H, OCH_2O), 6.26 (s, 2H, H2'6'), 6.54 (s, 1H, H8), 6.71 (s, 2H, $\text{CH}=\text{CH}$), 6.83 (s, 1H, H5). $^{13}\text{C-NMR}$ (75 MHz, CDCl_3) δ : 0.67, 33.59, 34.13, 37.93, 41.62, 44.11, 56.84, 66.87, 68.26, 68.38, 10 73.39, 74.38, 74.49, 100.17, 102.01, 102.54, 108.25, 109.51, 111.10, 128.38, 130.89, 133.28, 134.50, 134.66, 146.84, 147.59, 149.29, 170.64, 170.80, 175.38.


4'-(Maleimidopropionoyl)etoposide



15 Anal. RP-HPLC: t_R = 17.7 min (0 – 60 % MeCN gradient, purity > 99 %). $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ : 1.39 (d, J = 4.82 Hz, 3H, CH_3), 2.88 (m, 1H, H3), 2.96 (t, J = 7.24 Hz, 2H, CH_2 -Mim, 2.91 (m, 1H, H3), 3.34 (dd, J = 14.01, 5.26 Hz, 1H, H2), 3.36 (m, 2H, G4,5), 3.45-3.58 (m, 2H, G2,6), 3.92 (t, J = 3.20 Hz, 2H, CH_2 -Mim), 3.65 (s, 6H, OCH_3 x2), 3.76 (m, 1H, G3), 4.15-4.27 (m, 2H, H11, G6), 4.43 (m, 1H, H11), 20 4.62-4.67 (m, 2H, H1, G1), 4.75 (m, 1H, G7), 4.91 (d, J = 3.27 Hz, H4), 6.00 (d, J = 6.68 Hz, 2H, OCH_2O), 6.25 (s, 2H, H2'6'), 6.54 (s, 1H, H8), 6.71 (s, 2H, $\text{CH}=\text{CH}$), 6.82 (s, 1H, H5). $^{13}\text{C-NMR}$ (75 MHz, CDCl_3) δ : 20.62, 32.41, 33.94, 37.87, 41.61,


44.31, 56.52, 66.84, 68.44, 73.47, 74.13, 74.88, 80.06, 100.24, 102.10, 102.30, 107.89, 109.36, 111.22, 128.65, 132.68, 134.61, 138.28, 147.74, 149.29, 151.76, 168.90, 170.76, 175.56.

5 **G2-[Succinimidopropionoyl-(H-Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-OH)]etoposide**




To a solution of G2-(maleimidopropionoyl)etoposide (4.4 μ mol, 3.3 mg) and H-Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-OH (5.7 μ mol, 13.4 mg) in DMF (0.5 mL) was added Et₃N (0.7 μ L, 4.9 μ mol). The mixture was stirred for 30 min, diluted with 0.1 % aq TFA (1 mL) and purified by preparative RP-HPLC (0 – 60 % MeCN gradient) to afford the pure title compound as a colourless solid (10.8 mg, 80 %). Anal. RP-HPLC: t_R = 14.6 min (0 – 60 % MeCN gradient, purity > 98 %). DE MALDI-TOF MS: [M + H]⁺ = 3091.1 ($C_{143}H_{210}N_{36}O_{37}S_2$ = 3089.55).

G3-[Succinimidopropionoyl-(H-Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-OH)]etoposide



To a solution of G3-(maleimidopropionoyl)etoposide (3.1 μ mol, 2.3 mg) and H-Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-OH (4.3 μ mol, 10.2 mg) in DMF (0.5 mL) was added Et₃N (0.6 μ L, 4.4 μ mol). The mixture was 5 stirred for 30 min, diluted with 0.1 % aq TFA (1 mL) and purified by preparative RP-HPLC (0 – 60 % MeCN gradient) to afford the pure title compound as a colourless solid (7.4 mg, 79 %). Anal. RP-HPLC: t_R = 14.7 min (0 - 60% MeCN gradient, purity > 98 %). DE MALDI-TOF MS: [M + H]⁺ = 3090.3 (C₁₄₃H₂₁₀N₃₆O₃₇S₂ = 3089.55).

10 4'-[Succinimidopropionoyl-(H-Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-OH)]etoposide




To a solution of 4'-(maleimidopropionoyl)etoposide (4.8 μ mol, 3.6 mg) and H-Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-OH (5.9 μ mol, 15 13.9 mg) in DMF (0.5 mL) was added Et₃N (0.7 μ L, 5.1 μ mol). The mixture was stirred for 30 min, diluted with 0.1 % aq TFA (1 mL) and purified by preparative RP-

HPLC (0 – 60 % MeCN gradient) to afford the pure title compound as a colourless solid (11.2 mg, 77 %). Anal. RP-HPLC: $t_R = 14.6$ min (0 – 60 % MeCN gradient, purity > 99 %). DE MALDI-TOF MS: $[M + H]^+ = 3090.9$ ($C_{143}H_{210}N_{36}O_{37}S_2 = 3089.55$).

5

Example 21***O*-(Maleimidopropionyl)roscovitine**

10




15


A solution of roscovitine (29 μ mol, 10.3 mg), 3-maleimidopropionic acid (64 μ mol, 10.8 mg), DIC (35 μ mol, 4.4 mg) and DMAP (2 μ mol, 0.35 mg) in of pyridine (1 mL) was stirred for 40 min. The solvent was evaporated *in vacuo* and the resulting light-yellow solid was redissolved in CH_2Cl_2 , washed with water and brine and was dried on $MgSO_4$. The solvent was evaporated and the title compound was obtained as a light-yellow solid (14.1 mg, 96 %). This material was used without further purification in the next reaction.

20

***O*-[Succinimidopropionyl-(H-Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-OH)]roscovitine**




To a solution of *O*-(maleimidopropionoyl)roscovitine (28 μ mol, 14.1 mg) and H-Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-OH (14.9 μ mol, 35 mg) in DMF (1.5 mL) was added Et₃N (2 μ L, 14.5 μ mol). The mixture was 5 stirred for 1 h and was purified by preparative RP-HPLC (10 – 60 % MeCN gradient) to afford the pure title compound as a colourless solid (7.2 mg). Anal. RP-HPLC: t_R = 15.5 min (0 – 60 % MeCN gradient, purity > 98 %). DE MALDI-TOF MS: [M + H]⁺ = 2856.1 (C₁₃₃H₂₀₄N₄₂O₂₅S₂ = 2855.44).

Example 22***O*- β Ala-Bohemine**

A solution of bohemine (58.8 μ mol, 20 mg), Boc- β Ala-OH (0.128 mmol, 24.2 mg) DIC (70 μ mol, 8.8 mg) and DMAP (9.8 μ mol, 1.2 mg) in CH_2Cl_2 (2 mL) was stirred for 2.5 hrs. The solvent was evaporated *in vacuo* and the resulting white solid was purified by preparative RP-HPLC (10 – 70 % MeCN gradient) to afford *O*-(Boc- β Ala)bohemine as a colourless solid (30 mg). Anal. RP-HPLC: t_R = 19.8 min (0 – 60 % MeCN gradient, purity > 99 %). A solution of *O*-(Boc- β Ala)bohemine (7.6 mg) in 9:1 TFA/water (1 mL) was stirred for 1 h. The solvent was evaporated to dryness and the residue of title compound was used without further purification in the next reaction (purity by anal. RP-HPLC was > 98 %).

15

***O*-(β Ala-succinyl- β Ala-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-OH)bohemine**



A mixture of succinyl- β Ala-Arg(Pmc)-Gln(Trt)-Ile-Lys(Boc)-Ile-Trp-Phe-Gln(Trt)-Asn(Trt)-Arg(Pmc)-Arg(Pmc)-Met-Lys(Boc)-Trp-Lys(Boc)-Lys(Boc)-resin (14.9


μmol , 81.7 mg), *O*- β Ala-bohemine (14.9 μmol , 7.6 mg), PyBOP (14.9 μmol , 7.8 mg), HOBr (14.9 μmol , 2.4 mg) and DIEA (0.2295 mmol, 29.7 mg) in DMF (2 mL) was stirred for 2 h. The peptidyl resin was filtered, washed with DMF, CH_2Cl_2 and Et_2O and was dried *in vacuo* (82 mg). The product was treated with cleavage reagent (5 mL, 5 h). Crude product (42 mg) was obtained by precipitation with Et_2O and centrifugation/decantation. It was purified by preparative RP-HPLC (0 - 60% MeCN gradient) to afford the pure title compound as a colourless solid (14.3 mg). Anal. RP-HPLC: t_R = 14.8 min (0 - 60 % MeCN gradient, purity > 93 %). DE MALDI-TOF MS: $[\text{M} + \text{H}]^+$ = 2812.7 ($\text{C}_{132}\text{H}_{204}\text{N}_{42}\text{O}_{25}\text{S}$ = 2811.37).

10

Example 23

(Maleimidopropionoyl)bohemine


15



20

3-Maleimidopropionic acid (12.8 mg, 76 μmol) was dissolved in CH_2Cl_2 (1 mL). The mixture was stirred and DIC (5.3 mg, 42 μmol) in dry CH_2Cl_2 (0.5 mL) was added. The reaction was allowed to proceed with stirring for 40 min. Solvent was then removed under reduced pressure. The residue of 3-maleimidopropionic acid anhydride was redissolved in dry pyridine (0.5 mL). A solution of bohemine (10.3 mg, 30 μmol) and DMAP (0.35 mg, 2 μmol) in pyridine (0.5 mL) was added and the mixture was stirred under N_2 for 1 h. It was then evaporated to dryness under reduced pressure. The residue was redissolved in DMF (1 mL) and purified by preparative RP-HPLC column (10 - 60 % MeCN gradient) to afford the pure title compound as a colourless solid (14.7 mg, 88 %). Anal. RP-HPLC: t_R = 17.7 min (0 - 60 % MeCN gradient, purity > 95 %). $^1\text{H-NMR}$ (CDCl_3) and DE MALDI-TOF MS spectra were consistent with the proposed structure ($\text{C}_{25}\text{H}_{29}\text{N}_7\text{O}_4$ = 491.54).

O-[Succinimidopropionoyl-(H-Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-OH)]bohemine




5 (Maleimidopropionoyl)bohemine (0.74 mg, 1.5 μ mol) was dissolved in DMF (0.3 mL) and Et₃N (50 μ L) was added. H-Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-OH (3.5 mg, 1.5 μ mol), dissolved in DMF (0.25 mL) was then added. The mixture was stirred under N₂ and was monitored by anal. RP-HPLC. After 1 h, the reaction was complete. The mixture was filtered and purified by preparative

10 RP-HPLC (10 - 60 % MeCN gradient) to afford the pure title compound as a colourless solid (1.7 mg, 40 %). Anal. RP-HPLC: t_R = 15.0 min (0 - 60 % MeCN gradient; purity > 95 %). DE MALDI-TOF MS: [M + H]⁺ = 2842 (C₁₃₂H₂₀₂N₄₂O₂₅S₂ = 2841.42).

15

Example 24


4-(Iodoacetyl)podophyllotoxin



20 A mixture of podophyllotoxin (0.49 mmol, 204 mg), iodoacetic acid (1.03 mmol, 192 mg), DIC (0.552 mmol, 69.7 mg) and DMAP (0.164 mmol, 20 mg) in dry CH₂Cl₂ (5 mL) was cooled to 0 °C. Pyridine (0.2 mL) was added and the reaction mixture was

allowed to stir for 1 h at 0 °C. The mixture was evaporated to dryness. The resulting light-yellow residue was redissolved in MeCN and was purified by preparative RP-HPLC (20 – 70 % MeCN gradient) to afford the pure title compound as a colourless solid (89.5 mg). Anal. RP-HPLC: t_R = 22.3 min (0 – 60 % MeCN gradient, purity > 95 %). $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ : 2.85 (m, 2H, H2,3), 3.70 (s, 6H, $\text{OCH}_3 \times 2$), 3.72 (s, 2H, CH_2I), 3.74 (s, 3H, OCH_3), 4.13 (m, 1H, H11), 4.34 (m, 1H, H11), 4.53 (d, 1H, J = 3.60 Hz, H1), 5.83 (d, 1H, J = 8.43 Hz, H4), 5.93 (dd, 2H, J = 4.35, 1.17 Hz, OCH_2O), 6.31 (s, 2H, H2'6'), 6.48 (s, 1H, H8), 6.77 (s, 1H, H5).

10 4-[Acetyl-(H-Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-OH)]podophyllotoxin




To a solution of 4-(iodoacetyl)podophyllotoxin (17 μmol , 10 mg) and H-Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-OH (6 μmol , 14 mg) in 15 DMF (1 mL) was added Et_3N (0.9 μL , 6 μmol). The mixture was stirred for 1 h. MeCN (0.5 mL) was added and the solution was purified by preparative RP-HPLC (10 – 60 % MeCN gradient) to afford the pure title compound as a colourless solid (9.9 mg, 59 %). Anal. RP-HPLC: t_R = 15.4 min (0 – 60 % MeCN gradient, purity > 97 %). DE MALDI-TOF MS: $[\text{M} + \text{H}]^+ = 2806.8$ ($\text{C}_{131}\text{H}_{195}\text{N}_{35}\text{O}_{30}\text{S}_2 = 2804.30$).

20

Example 25

4-[Acetyl-(H-Cys- β Ala-Arg-Arg-Met-Lys-Trp-Lys-Lys-NH₂)]podophyllotoxin




A solution of 4-(iodoacetyl)podophyllotoxin (17 μ mol, 10 mg) and H-Cys-bAla-Arg-Arg-Met-Lys-Trp-Lys-Lys-NH₂ (23 μ mol, 28.6 mg) in DMF (1 mL) was added Et₃N (2.4 μ L, 17 μ mol). After stirring for 1 h MeCN (0.5 mL) was added and the mixture 5 was purified by preparative RP-HPLC (0 – 60 % MeCN gradient) to afford the pure title compound as a colourless solid (29.4 mg, 100 %). Anal. RP-HPLC: t_R = 14.1 min (0 – 60 % MeCN gradient, purity > 98 %). DE MALDI-TOF MS: [M + H]⁺ = 1661.0 (C₇₆H₁₁₄N₂₀O₁₈S₂ = 1659.97).

10

Example 26


4'-Demethyl-4-(iodoacetyl)epipodophyllotoxin



15 To a solution of 4'-demethylepipodophyllotoxin (0.26 mmol, 104 mg), iodoacetic acid (0.53 mmol, 98.8 mg), and DIC (0.32 mmol, 40.1 mg) in CH₂Cl₂ (2 mL) at 0 °C was added pyridine (50 μ L) and DMAP (0.1 mmol, 12.8 mg). After 1 h stirring the solvents were evaporated. The residue was redissolved in DMF (1 mL) and purified by preparative RP-HPLC (20 – 60 % MeCN gradient) to afford the pure title compound as 20 a colourless solid (35.7 mg, 24 %). Anal. RP-HPLC: t_R = 20.3 min (0 – 60 % MeCN gradient, purity > 96 %). ¹H-NMR (300 MHz, CDCl₃) δ : 3.02 (m, 1H, H3), 3.20 (m,

1H, H2), 3.71 (s, 6H, OCH₃×2), 3.63 (s, 2H, CH₂I), 3.74 (s, 3H, OCH₃), 4.05 (m, 1H, H11), 4.27 (m, 1H, H11), 4.60 (d, 1H, *J* = 4.94 Hz, H1), 6.06 (d, 1H, *J* = 3.41 Hz, H4), 5.92 (m, 2H, OCH₂O), 6.21 (s, 2H, H2'6'), 6.49 (s, 1H, H8), 6.80 (s, 1H, H5).

5 **4'-Demethyl-4-[acetyl-(H-Cys-βAla-Arg-Arg-Met-Lys-Trp-Lys-Lys-NH₂)]epipodophyllotoxin**




To a solution of 4'-demethyl-4-(iodoacetyl)epipodophyllotoxin (17.6 µvmmol, 10 mg) and H-Cys-βAla-Arg-Arg-Met-Lys-Trp-Lys-Lys-NH₂ (14.9 µmol, 18 mg) in DMF (1mL) was added Et₃N (2.1 mL, 15 µmol). After stirring for 1 h the reaction mixture was purified by preparative RP-HPLC (0 - 60% MeCN gradient) to afford the pure title compound as a colourless solid (11.2 mg, 46 %). Anal. RP-HPLC: *t*_R = 12.8 min (0 - 60 % MeCN gradient, purity > 98 %). DE MALDI-TOF MS: [M + H]⁺ = 1647.2 (C₇₅H₁₁₂N₂₀O₁₈S₂ = 1645.95).

15

Example 27

20 **4'-Demethyl-4-[acetyl-(H-Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-NH₂)]epipodophyllotoxin**




To a solution of 4'-demethyl-4(iodoacetyl)epipodophyllotoxin (22 μ mol, 12.6 mg) and H-Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-NH₂ (8 μ mol, 20 mg) in DMF (1 mL) was added Et₃N (1.2 μ L, 9 μ mol). After stirring for 1 h 5 the mixture was purified by preparative RP-HPLC (0 – 60 % MeCN gradient) to afford the pure title compound as a colourless solid (13.3 mg, 56 %). Anal. RP-HPLC: t_R = 14.5 min (0 – 60 % MeCN gradient, purity > 96 %). DE MALDI-TOF MS: [M + H]⁺ = 2789.5 ($C_{130}H_{194}N_{36}O_{29}S_2$ = 2789.29).

10


Example 28

4-(Boc-Gly)podophyllotoxin



15 A mixture of podophyllotoxin (400 mg, 0.97 mmol), Boc-Gly-OH (510 mg, 2.91 mmol) DIC (1.73 mmol, 273 μ L), DMAP (0.41 mmol, 50 mg) and pyridine (173 μ L) in CH₂Cl₂ (5 mL) was stirred at for 1 h. The solvents were evaporated. The residue was redissolved in DMF (1.5 mL) and purified by RP-HPLC (20 – 70 % MeCN gradient) to afford the pure title compound as a colourless solid (502.6 mg, 91 %).
20 Anal. RP-HPLC: t_R = 22.1 min (0 – 60 % MeCN gradient, purity > 97 %).

4-(H-Gly)podophyllotoxin




To a solution of 4-(Boc-Gly)podophyllotoxin (0.24 mmol, 137 mg) in CH_2Cl_2 (8 mL) was added TFA (0.5 mL). After stirring for 1 h the solvents were evaporated. The resulting light-yellow solid residue was purified by preparative RP-HPLC (10 – 70 %

5 MeCN gradient) to afford the pure title compound as a colourless solid (41.7 mg, 37 %). Anal. RP-HPLC: t_R = 15.2 min (0 – 60 % MeCN gradient, purity > 97 %).

10


4-(Maleimidopropionoyl-Gly)podophyllotoxin



To a solution of 3-maleimidopropionic acid (70 μmol , 11.8 mg) and DIC (38 μmol , 4.83 mg) in DMF (1 mL) was added 4-(H-Gly)podophyllotoxin (17 μmol , 8 mg), DMAP (10 μmol , 1.2 mg) and pyridine (20 μL). After stirring for 1 h the mixture was purified by preparative RP-HPLC (0 – 60 % MeCN gradient) to afford the pure title compound as a colourless solid (1.1 mg). Anal. RP-HPLC: t_R = 18.2 min (0 – 60 % MeCN gradient, purity >97%).

20

4-[(Succinimidopropionoyl-Gly)-(H-Cys-bAla-Arg-Arg-Met-Lys-Trp-Lys-Lys-NH₂)]podophyllotoxin




To a solution of 4-(maleimidopropionoyl-Gly)podophyllotoxin (1.8 μ mol, 1.1 mg) and H-Cys- β Ala-Arg-Arg-Met-Lys-Trp-Lys-Lys-NH₂ (4 μ mol, 5 mg) in DMF (1 mL) was added Et₃N (0.5 μ L, 4 μ mol). The mixture was stirred for 1 h. It was diluted with 5 MeCN (0.5 mL) and purified by preparative RP-HPLC (0 – 60 % MeCN gradient) to afford the title compound as a colourless solid (1.1 mg, 33 %). Anal. RP-HPLC: t_R = 14.7 min (0 – 60 % MeCN gradient, purity > 97 %). DE MALDI-TOF MS: [M + H]⁺ = 1829.8 ($C_{83}H_{122}N_{22}O_{21}S_2$ = 1828.12).

10

Example 29


10-O-(Maleimidopropionoyl)camptothecin



15 To a solution of 10-hydroxycamptothecin (40 μ mol, 14.7 mg), 3-maleimidopropionic acid (0.228 mmol, 38.5 mg) and DIC (0.125 mmol, 15.8 mg) in CH₂Cl₂ (2 mL) was added pyridine (0.2 mL). After stirring for 1 h, the mixture was evaporated to dryness. The resulting light-yellow solid was redissolved in DMF (1 mL) and purified by preparative RP-HPLC (10 – 70 % MeCN gradient) to afford the pure title compound 20 (9.2 mg, 45 %) as a light-yellow solid. Anal. RP-HPLC: t_R = 15.7 min (0 – 60 % MeCN gradient, purity > 97 %). ¹H-NMR (300 MHz, CDCl₃) δ : 1.05 (t, 3H, J = 7.5

Hz, CH₃), 1.91 (m, 2H, *J* = 7.8 Hz, CH₂), 2.98 (t, 2H, *J* = 7.8 Hz, CH₂), 4.04 (t, 2H, *J* = 7.8 Hz, CH₂), 5.32 (m, 3H, H5, H17), 6.77 (s, 2H, CH=CH), 7.60 (m, 1H, H11), 7.72 (m, 2H, H14, H9), 8.24 (d, 1H, *J* = 9.2 Hz, H12), 8.36 (s, 1H, H7).

5 **10-*O*-[Succinimidopropionoyl-(H-Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-NH₂)]camptothecin**



To a solution of 10-*O*-(maleimidopropionoyl)camptothecin (9 μ mol, 4.6 mg) and H-Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-NH₂ (4 μ mol, 10 mg) in DMF (1 mL) was added Et₃N (0.55 μ L, 4 μ mol). After stirring for 1 h, the mixture was purified by preparative RP-HPLC (0 – 60 % MeCN gradient) to afford the pure title compound as a colourless solid (6.5 mg, 57 %). Anal. RP-HPLC: *t*_R = 14.0 min (0 - 60% MeCN gradient, purity > 98 %). DE MALDI-TOF MS: [M + H]⁺ = 2864.7 (C₁₃₄H₁₉₅N₃₉O₂₈S₂ = 2864.36).

15


Example 30

H-Cys-Arg-Arg-Met-Lys-Trp-Lys-Lys-Cys-NH₂

20 Starting from Rink Amide AM resin (0.69 mmol/g, Novabiochem), H-Cys(Trt)-Arg(Pmc)-Arg(Pmc)-Met-Lys(Boc)-Trp-Lys(Boc)-Lys(Boc)-Cys(Trt)-resin was assembled. After deprotection (1.5 h), the crude peptide was obtained by precipitation from Et₂O, centrifugation/decantation, and drying. Aliquots (total 258 mg) were purified by preparative RP-HPLC (9 – 19 % MeCN gradient) to afford the pure title 25 compound (132.4 mg). Anal. RP-HPLC: *t*_R = 20.3 min (8 – 18 % MeCN gradient, purity > 99 %, λ = 214 nm). DE MALDI-TOF MS: [M + H]⁺ = 1238.6

$(C_{52}H_{92}N_{20}O_{9}S_3 = 1237.63)$.

Bis-[4-(succinimidopropionoyl)podophyllotoxin]-(H-Cys-Arg-Arg-Met-Lys-Trp-Lys-Lys-Cys-NH₂)



5


To a solution of 4-(maleimidopropionoyl)podophyllotoxin (19 μ mol, 11 mg) and H-Cys-Arg-Arg-Met-Lys-Trp-Lys-Lys-Cys-NH₂ (12 μ mol, 15 mg), in DMF (1 mL) was added Et₃N (2.8 μ L). After stirring for 1 h the mixture was purified by preparative RP-HPLC (10 – 70 % MeCN gradient) to afford the pure title compound as a colourless solid (9.0 mg, 32 %). Anal. RP-HPLC: $t_R = 17.4$ min (0 – 60 % MeCN gradient, purity > 98 %). DE MALDI-TOF MS: $[M + H]^+ = 2369.7$ ($C_{110}H_{146}N_{22}O_{31}S_3 = 2368.66$).

10

Example 31

15

4'-(Succinimidopropionoyl)epipodophyllotoxin-(H-Cys-Arg-Arg-Met-Lys-Trp-Lys-Lys-Cys-NH₂)-10-O-(succinimidopropionoyl)camptothecin




To a solution of 10-O-(maleimidopropionyl)camptothecin (0.005 mmol, 2.6 mg), 4'-
(maleimidopropionyl) epipodophyllotoxin (5.6 μ mol, 3.1 mg), and H-Cys-Arg-Arg-
Met-Lys-Trp-Lys-Lys-Cys-NH₂ (11 μ mol, 13 mg), in DMF (1.5 mL) was added Et₃N

5 (1.5 μ L). After stirring for 1.5 h the mixture was purified by preparative RP-HPLC
(10 – 70 % MeCN gradient) to afford the pure title compound as a colourless solid
(1.9 mg). Anal. RP-HPLC: t_R = 14.8 min (0 – 60 % MeCN gradient, purity > 96 %).
DE MALDI-TOF MS: [M + H]⁺ = 2304.6 (C₁₀₇H₁₃₈N₂₄O₂₈S₃ = 2304.58).

10

Example 32

4'-(Succinimidopropionyl)epipodophyllotoxin-(H-Cys-Arg-Arg-Met-Lys-Trp-Lys-Lys-Cys-NH₂)-2'-(succinimidopropionyl)paclitaxel



15


To a solution of 4'-(succinimidopropionoyl-(H-Cys-Arg-Arg-Met-Lys-Trp-Lys-Lys-Cys-NH₂)]epipodo-phyllotoxin (2 μmol, 3.5 mg), 2'-(maleimidopropionyl)paclitaxel (2 μmol, 2 mg) in DMF (1 mL) was added Et₃N (0.3 μL). After stirring for 1.5 h the reaction mixture was purified by preparative RP-HPLC (10 – 70 % MeCN gradient) to afford the pure title compound as a colourless solid (1.5 mg). Anal. RP-HPLC: t_R = 17.8 min (0 – 60 % MeCN gradient, purity > 98 %). DE MALDI-TOF MS: [M+H]⁺ = 2794.5 (C₁₃₄H₁₇₃N₂₃O₃₇S₃ = 2794.14).

10 **Example 33**

4'-Methoxy-(4''-aminoanilino)epipodophyllotoxin and 4'-demethyl-(4''-aminoanilino) epipodophyllotoxin

A solution of podophyllotoxin (3.6 mmol, 1.5 g) in ClCH₂CH₂Cl (15 mL) was kept at 15 0 °C and HBr gas was passed through the solution. After 45 min, N₂ was passed through the reaction mixture to drive off excess HBr. To this solution anhydrous barium carbonate (4.32 mmol, 0.85 g) and 4-nitroaniline (4.32 mmol, 0.6 g) were added. The mixture was stirred at ambient temperature for 18 h under N₂. It was diluted with EtOAc and filtered. The filtrate was washed with water, dried on MgSO₄, 20 and purified by flash chromatograph (100:5:5 CH₂Cl₂/EtOAc/acetone) to afford crude 4'-methoxy-(4''-nitroanilino)epipodophyllotoxin and 4'-demethyl-(4''-nitroanilino)epipodophyllotoxin. Further purification by preparative RP-HPLC (10 – 70 % MeCN gradient) afforded the pure products as yellow solids.


25 **4'-Methoxy-4-(4''-nitroanilino)epipodophyllotoxin**



Anal. RP-HPLC: t_R = 22.3 min (0 – 60 % MeCN gradient, purity > 95 %). ¹H-NMR (300 MHz, CDCl₃) δ: 3.09 (m, 2H, H2,3), 3.77 (s, 6H, OCH₃), 3.83 (s, 3H, OCH₃),

3.86 (m, 1H, H11), 4.42 (m, 1H, H11), 4.63 (m, 2H, H1,4), 4.84 (m, 1H, NH), 6.00 (m, 2H, OCH₂O), 6.31 (s, 2H, H2',6'), 6.57 (m, 3H, H8, Ar), 6.76 (s, 1H, H5), 8.16 (d, 2H, J=9.08 Hz, Ar).

5 4'-Demethyl-4-(4"-nitroanilino)epipodophyllotoxin




Anal. RP-HPLC for: t_R = 20.5 min (0 – 60 % MeCN gradient, purity > 95 %). ¹H-NMR (300 MHz, CDCl₃) δ : 3.07 (m, 2H, H2,3), 3.79 (s, 6H, OCH₃), 3.81 (m, 1H, H11), 4.40 (m, 1H, H11), 4.60 (m, 2H, H1), 4.73 (m, 1H, H4), 4.83 (m, 1H, NH), 5.45 (br, 1H, OH), 5.98 (m, 2H, OCH₂O), 6.31 (s, 2H, H2',6'), 6.57 (m, 3H, H8, Ar), 6.76 (s, 1H, H5), 8.14 (d, 2H, J = 9.04 Hz, Ar).

To a solution of 4'-methoxy-4-(4"-nitroanilino)epipodophyllotoxin or 4'-demethyl-(4"-nitroanilino)epipodophyllotoxin in 10:1 EtOAc/MeOH was added 10 % palladium on activated carbon. The mixture was stirred under H₂ for 3 h. The catalyst was filtered and washed several times with MeOH. The combined filtrate and washing were evaporated to dryness to give a light-yellow solid which was redissolved in MeCN and purified by preparative RP-HPLC (10 – 70 % MeCN gradient) to afford the products as yellow solids in a quantitative yield.

20


4'-Methoxy-4-(4"-aminoanilino)epipodophyllotoxin



Anal. RP-HPLC: t_R = 16.1 min (0 – 60 % MeCN gradient, purity > 95 %). ¹H-NMR (300 MHz, CDCl₃) δ : 287 (m, 1H, H3), 3.11 9m, 1H, H2), 3.68 (s, 6H, OCH₃), 3.73 (s, 3H, OCH₃), 3.61 (m, 1H, H11), 4.15 (m, 1H, H11), 4.52-4.62 (m, 2H, H1,4), 5.86 (m,


2H, OCH₂O), 6.28 (s, 2H, H2',6'), 6.37 (m, 2H, Ar), 6.45 (s, 1H, H8), 6.69 (s, 1H, H5), 7.03 (m, 2H, Ar).

4'-Demethyl-4-(4"-aminoanilino)epipodophyllotoxin




Anal. RP-HPLC: t_R = 14.2 min (0 – 60 % MeCN gradient, purity > 97 %). ¹H-NMR (300 MHz, CDCl₃) δ : 3.05 (m, 1H, H3), 3.18 (m, 1H, H2), 3.78 (s, 6H, OCH₃), 3.93 (m, 1H, H11), 4.38 (m, 1H, H11), 4.60 (d, 1H, J = 5.91 Hz, H1), 4.70 (d, 1H, J = 3.86 Hz, H4), 5.96 (m, 2H, OCH₂O), 6.33 (s, 2H, H2',6'), 6.53 (s, 1H, H8), 6.62 (d, 2H, J = 8.66 Hz, Ar), 6.75 (s, 1H, H5), 7.19 (d, 2H, J = 8.60 Hz, Ar).

4'-Methoxy-4-[4"-aminoanilino-(maleimidopropionoyl)]epipodophyllotoxin



To a solution of 4'-methoxy-4-(4"-aminoanilino)epipodophyllotoxin (41 μ mol, 20.8 mg), 3-maleimidopropionic acid (0.226 mmol, 38.2 mg), DIC (0.124 mmol, 15.7 mg) and DMAP (40 μ mol, 4.9 mg) in CH₂Cl₂ (2 mL) was added pyridine (0.2 mL). After stirring for 1 h, the mixture was evaporated to dryness. The resulting light-yellow solid was redissolved in DMF (1 mL) and purified by preparative RP-HPLC (20 – 70 % MeCN gradient) to afford the pure title compound as a colourless solid (10.1 mg, 38 %). Anal. RP-HPLC: t_R = 19.5 min (0 – 60 % MeCN gradient, purity > 96 %). ¹H-NMR (300 MHz, CDCl₃) δ : 2.71 (t, 2H, J = 7.0 Hz, CH₂), 2.91 (m, 1H, H3), 3.14 (m, 1H, H2), 3.76 (s, 6H, OCH₃), 3.82 (s, 3H, OCH₃), 3.93 (t, 2H, J = 7.0 Hz, CH₂), 3.97 (m, 1H, H5, H11), 3.49 (m, 1H, H11), 4.63 (m, 2H, H1,4), 5.97 (m, 2H, OCH₂O), 6.32 (s, 2H, H2',6'), 6.50 (m, 2H, Ar), 6.53 (s, 1H, H8), 6.73 (s, 2H, CH=CH), 6.74 (s, 1H, H5), 7.32 (m, 2H, Ar).

4'-Methoxy-4-[4''-aminoanilino-(succinimidopropionoyl)-(H-Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-NH₂)]epipodophyllotoxin




5

To a solution of 4'-methoxy-4-[4''-aminoanilino-(maleimidopropionoyl)]epipodophyllotoxin, (6 μ mol, 4.1 mg) and H-Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-NH₂ (6 μ mol, 14 mg) in DMF (1 mL) was added Et₃N (2 μ L). After stirring for 1 h, the mixture was purified by 10 preparative RP-HPLC (0 – 60 % MeCN gradient) to afford the pure title compound as a colourless solid (5.8 mg, 32 %). Anal. RP-HPLC: t_R = 16.0 min (0 – 60 % MeCN, purity > 99 %). DE MALDI-TOF MS: [M + H]⁺ = 3003.9 ($C_{142}H_{207}N_{39}O_{30}S_2$ = 3004.54).

15

Example 34

4'-Methoxy-4-[4''-aminoanilino-(succinimidopropionoyl)-(H-Cys- β Ala-Arg-Arg-Met-Lys-Trp-Lys-Lys-NH₂)]epipodophyllotoxin




To a solution of 4'-methoxy-[4''-aminoanilino-(maleimidopropionoyl)]epipodophyllotoxin (7 μ mol, 4.6 mg) and H-Cys- β Ala-Arg-Arg-Met-Lys-Trp-Lys-Lys-NH₂ (14 μ mol, 16.3 mg) in DMF (1 μ L) was added Et₃N 5 (1 mL). After stirring for 1 h, the mixture was purified by preparative RP-HPLC (0 – 60 % MeCN gradient) to afford the pure title compound as a colourless solid (6.4 mg, 49 %). Anal. RP-HPLC: t_R = 15.2 min (0 – 60 % MeCN gradient, purity > 98 %). DE MALDI-TOF MS: [M + H]⁺ = 1861.6 ($C_{87}H_{125}N_{23}O_{19}S_2$ = 1861.20).

10

Example 35

4'-Demethyl-4-[4''-aminoanilino-(maleimidopropionoyl)]epipodophyllotoxin




15 To a solution of 4'-demethyl-4-(4''-aminoanilino)epipodophyllotoxin (24 μ mol, 12 mg), 3-maleimidopropionic acid (49 μ mol, 8.3 mg), and DIC (27 μ mol, 3.4 mg) in 1:1 DMF/CH₂Cl₂ (2 mL) was added pyridine (10 μ L). After stirring for 1 h, the reaction mixture was evaporated. The resulting light-yellow solid was purified by preparative RP-HPLC (10 – 70 % MeCN gradient) to afford the pure title compound as a colourless solid (5.3 mg, 34 %). Anal. RP-HPLC: t_R = 19.5 min (0 – 60 % MeCN gradient, purity > 96 %). ¹H-NMR (300 MHz, CDCl₃) δ : 2.65 (t, 2H, J = 7.3 Hz, CH₂), 20

2.98 (m, 1H, H3), 3.17 (m, 1H, H2), 3.79 (s, 6H, OCH₃), 3.93 (t, 2H, *J* = 7.0 Hz, CH₂), 3.99 (m, 1H, H5, H11), 4.38 (m, 1H, H11), 4.58 (d, 1H, *J* = 4.95 Hz, H1), 4.64 (d, 1H, *J* = 3.95 Hz, H4) 5.96 (m, 2H, OCH₂O), 6.33 (s, 2H, H2'6'), 6.49-6.53 (m, 3H, H8, Ar), 6.74 (s, 2H, CH=CH), 6.75 (s, 1H, H5), 7.33 (m, 2H, Ar).

5

4'-Demethyl-4-[4''-aminoanilino-(succinimidopropionoyl)-(H-Cys-βAla-Arg-Arg-Met-Lys-Trp-Lys-Lys-NH₂)]epipodophyllotoxin



To a solution of 4'-demethyl-[4''-aminoanilino-

10 (maleimidopropionoyl)]epipodophyllotoxin (8.3 μmol, 5.3 mg) and H-Cys-βAla-Arg-Arg-Met-Lys-Trp-Lys-Lys-NH₂ (13 μmol, 15.6 mg) in DMF (1.5 mL) was added Et₃N (2 μL). After stirring for 1 h, the mixture was purified by preparative RP-HPLC (0 – 60 % MeCN gradient) to afford the pure title compound as a colourless solid (14.9 mg, 97 %). Anal. RP-HPLC: *t*_R = 13.7 min (0 – 60 % MeCN gradient, purity > 98 %).

15 DE MALDI-TOF MS: [M + H]⁺ = 1847.1 (C₈₆H₁₂₃N₂₃O₁₉S₂ = 1847.17).

Example 36

20 *In vitro* cytotoxic activity of {[4[N-(2,4-diamino-6-pteridinyl-methyl)-N-methylamino]benzoyl]-Glu-Gly-βAla}₄-Lys₂-Lys-βAla-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-OH

This compound (abbreviated 'MTX-Pen' in the tables below) was evaluated for its ability to inhibit cell proliferation of normal (immortalised) human cells (HaCaT cells, *Tables 1 & 2*) and a human colorectal cancer cell line (HT29, *Table 3*). The free drug methotrexate ('MTX' in *Tables 1 – 3*) and the free vector H-Ala-Arg-Gln-Ile-Lys-Ile-5 Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-OH (abbreviated 'Pen' in *Table 1* below) were included for the purposes of comparison.

Assay procedure – Cells were seeded into 96-well plates at 2,500 cells/well in DMEM with 10 % FCS and antibiotics. After overnight incubation, test compound dilutions in 10 cell medium were prepared and were added to the cells. Samples were taken 1, 2, 3, and 4 days after compound addition. Nucleotide Releasing Reagent (LumiTech ViaLight kit) was added in order to lyse the cells and release ATP. After incubation at room temperature (5 min), the mixtures were transferred to opaque 96-well plates and stored at –20 °C until analysis. After loading plates into a luminometer (Lucy 1, 15 Labtech International), ATP Monitoring Reagent (20 µL/well, LumiTech ViaLight kit) was added to each well successively and light intensity was measured immediately. Six readings were taken per sample. Each assay point was established using six replicates and appropriate controls. ATP bioluminescence was found to be proportional to viable cell count over the entire cells/well range used.

20 Statistically significant results in the tables below are printed in bold face.

Table 1 (HaCaT Cells)

Dose (µM)	% Cell Death															
	Day 1				Day 2				Day 3				Day 4			
	MTX	MTX-Pen	Pen	MTX	MTX-Pen	Pen	MTX	MTX-Pen	Pen	MTX	MTX-Pen	Pen	MTX	MTX-Pen	Pen	
40.0	4	29	16	15	82	-22	79	97	5	92	98	12				
13.3	22	-42	18	35	63	0	82	97	-17	92	98	-6				
4.4	4	-8	8	24	45	-4	77	95	-1	93	98	10				
1.5	13	-24	16	31	82	-31	77	82	2	94	88	-14				
0.5	-4	-19	6	31	2	-6	75	29	-29	93	49	-26				
0.2	7	14	26	11	21	0	79	20	-3	93	51	21				

Table 2 (HaCaT Cells)

Dose (μ M)	% Cell Death							
	Day 1		Day 2		Day 3		Day 4	
	MTX	MTX-Pen	MTX	MTX-Pen	MTX	MTX-Pen	MTX	MTX-Pen
40.0		42		88		95		94
13.3		27		87		95		94
4.4	21	15	70	52	97	95	92	88
1.5	14	19	67	12	96	-16	91	17
0.5	0	13	59	24	96	-27	91	2
0.2	3		41		94		86	
0.1	19		7		45		65	

Table 3 (HT 29 Cells)

Dose (μ M)	% Cell Death							
	Day 1		Day 2		Day 3		Day 4	
	MTX	MTX-Pen	MTX	MTX-Pen	MTX	MTX-Pen	MTX	MTX-Pen
40.0		31		79		96		98
13.3		3		45		88		96
4.4	-14	10	-4	6	58	46	86	77
1.5	17	16	-5	9	48	15	84	45
0.5	15	14	-12	8	52	17	88	16
0.2	10		-5		54		85	
0.1	6		-17		52		84	

Example 37

10 Stabilisation of microtubule formation by paclitaxel and 2'-[Succinimidopropionoyl-(H-Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-OH)]paclitaxel

Assay procedure. – A solution of bovine tubulin and tetramethylrhodamine-labeled tubulin (total concentration 0.5 mg/mL) in G-PEM buffer (80 mM PIPES, pH 6.8, 1 mM EDTA, 1 mM GTP) was incubated in the presence of 10 μ M paclitaxel (A in Figure 1 below), 10 μ M 2'-[succinimidopropionoyl-(H-Cys-Arg-Gln-Ile-Lys-Ile-Trp-

Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-OH)]paclitaxel (B), or without test compound (C) for 30 min at 37 °C. Formation of microtubules was visualised on a Nikon Eclipse E800 fluorescence microscope. Images were captured with a Kodak DCS 420 digital camera and analysed using Adobe 5.0 software.

5

Example 38

Internalisation of 4-[succinimidopropionoyl-(biotinamidocaproyl-βAla-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Gly-Cys-Gly-NH₂)]podophyllotoxin into cells

A549 cells were seeded into 96-well plates at 50,000 cells per well in DMEM with 10 % FCS and antibiotics. After overnight incubation, 4-[succinimidopropionoyl-(biotinamidocaproyl-βAla-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Gly-Cys-Gly-NH₂)]podophyllotoxin (labelled 'conjugate' in *Figure 2* below) or biotinamidocaproyl-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Gly-Cys-Gly-NH₂ (labelled 'vector') were prepared as a dilution series of six decreasing concentrations in cell medium and were added to cells. At the end of the incubation period (60 min), the cells were rinsed three times with PBS and fixed for 20 min at -20 °C in ethanol/acetic acid (95/5). After the fixation, the cells were permeabilised for 10 min with PBS containing 3 % Tween-20. Endogenous alkaline phosphatase was neutralised by incubating the plate at 65 °C for 60 min. Cells were incubated for 30 min at room temperature with alkaline phosphatase-streptavidine (Pierce Chemical Co.) in 0.1 % BSA in PBS and were washed extensively with PBS. A freshly made solution of 1 mg/mL nitrophenyl phosphate in 10 mM diethanolamine (pH 9.5), 0.5 mM MgCl₂ was added to each well and incubated until sufficient colour developed (approximately 30 min). The enzymatic reaction was stopped by adding 50 µl 2 M aq NaOH. Alkaline phosphatase activity was measured spectrophotometrically at 405 nm.

Example 39

5 **Visualisation of cell internalisation by 4-[Succinimidopropionoyl-(biotinamidocaproyl- β Ala-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-Gly-Cys-Gly-NH₂)]podophyllotoxin**

Cells were seeded into 8-well chamber slides at 50,000 cells per well in DMEM with 10 % foetal calf serum and antibiotics. After overnight incubation, 4-[Succinimidopropionoyl-(biotinamidocaproyl- β Ala-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-Gly-Cys-Gly-NH₂)]podophyllotoxin was prepared in cell medium at a concentration of 10 μ M and was added to cells. At the 15 end of the incubation period (60 min), the cells were rinsed three times with PBS and fixed for 20 min at -20 °C in ethanol/acetic acid (95/5). After the fixation, the cells were permeabilised for 10 min with PBS containing 3 % Tween-20. The slides were incubated with streptavidin-FITC (Pierce Chemical Co.), diluted in PBS for 30 min. at room temperature, washed extensively with PBS and mounted in Hydromount (BDH). The distribution of the fluorescence was analysed on a Nikon Eclipse E800 20 fluorescence microscope. Images were captured with a Kodak DCS 420 digital camera and analysed using Adobe 5.0 software. A representative image is shown in *Figure 3*.

Example 40

25 **Intracellular stability of 4-[succinimidopropionoyl-(H-Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-NH₂)]podophyllotoxin**

10 \times 10⁶ HL60 cells were incubated for 1 h with 15 μ M 4-[succinimidopropionoyl-(H-Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-NH₂)]podophyllotoxin (A in *Figure 4* below) or without test compound (B) in DMEM. 30 After the incubation, cells were washed extensively with PBS until no test compound was detectable in the washes. Cells were incubated for one additional h with neat

medium. Afterwards the cells were pelleted, resuspended in 50 mM Tris pH 7.5, containing a cocktail of protease inhibitors and they were solubilised by ultrasonication for 1 min. The insoluble fraction was pelleted for 15 min using an Eppendorf centrifuge and the supernatant was analysed by anal. RP-HPLC (0 – 60 % 5 MeCN gradient, λ = 254 nm). Intact test compound was identified by reference to chromatograms obtained with authentic test compound and by DE MALDI-TOF MS analysis of the peak fraction indicated with an arrow in *Figure 4*. Pellets were further extracted with DMSO and extracts analysed similarly, no test compound was detected.

10 **Example 41**

Serum stability of peptide vectors

Test compounds were dissolved in cell-conditioned tissue culture medium (10 % FCS 15 in DMEM) at concentrations varying from 1 to 40 μ M. The solutions were incubated at 37 °C and samples were withdrawn at intervals. After filtration, aliquots were analysed by RP-HPLC (using a photodiode array UV detector). Intact vectors were identified by reference to chromatograms obtained with authentic peptides and by DE MALDI-TOF analysis of appropriate peak fractions. The half-lives for four different 20 vectors are summarised in *Table 4*. Similar results were obtained when human or murine serum was substituted for bovine serum (FCS). The latter was chosen preferentially in order to replicate the conditions used for cytotoxicity assays on cell cultures. In all cases the main metabolism product of the 16mer peptide acid H-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-OH was the 15mer 25 resulting from C-terminal truncation of a Lys residue. This 15mer peptide was observed to survive for several h prior to further carboxy-terminal degradation. The L-amino acid-containing vector peptide amides were degraded much more slowly, no individual metabolites could be identified. All D-amino acid-containing peptide vectors studied were very stable and could usually still be detected after 72 h 30 incubations.

Table 4

Vector	Serum <i>t</i> _{1/2}
H-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-OH	10 min
H-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-NH ₂	> 12 h
H-D-Arg-D-Gln-D-Ile-D-Lys-D-Ile-D-Trp-D-Phe-D-Gln-D-Asn-D-Arg-D-Arg-D-Met-D-Lys-D-Trp-D-Lys-D-Lys-NH ₃	> 24 h
H-Arg-Arg-Met-Lys-Trp-Lys-Lys-NH ₂	3 h

5

Example 42**Serum stability of drug-ester linkages**

10 Test compounds (*Table 5*: A, 4-[succinimidopropionoyl-(H-Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-NH₂)]podophyllotoxin; B, 4-[acetyl-(H-Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-OH)]podophyllotoxin; C, 2'-[succinimidopropionoyl-(H-Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-NH₂)]paclitaxel) were dissolved in cell-conditioned tissue culture medium (10 % FCS in DMEM) at concentrations varying from 1 to 40 µM. The solutions were incubated at 37 °C and samples were withdrawn at intervals. After filtration, aliquots were analysed by RP-HPLC (using a photodiode array UV detector). Hydrolysis of the ester bonds between the drug hydroxy groups and the linker carboxyl groups was assessed by appearance of free podophyllotoxin or paclitaxel. The half-lives for three different drug-linker combinations are summarised in *Table 5*. Similar results were obtained when human or murine serum was substituted for bovine serum (FCS). The latter was chosen

preferentially in order to replicate the conditions used for cytotoxicity assays on cell cultures.

Table 5

Entry	Structure	Serum $t_{1/2}$ of Drug-Linker Ester bond
A		> 24 h
B		40 min
C		> 12 h

Example 43**Comparison of cytotoxic activities of paclitaxel and its vector conjugates**

5 In order to demonstrate the cytotoxic biological effect on cancer cells (A549 lung carcinoma and MCF7 breast carcinoma cell lines in *Table 6*) of the paclitaxel-conjugates (paclitaxel-(16mer vector), 2'-[succinimidopropionoyl-(H-Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Gly-Cys-Gly-NH₂)]paclitaxel; paclitaxel-(7mer vector), 2'-[succinimidopropionoyl-(H-Cys-βAla-10 Arg-Arg-Met-Lys-Trp-Lys-NH₂)]paclitaxel), cells were exposed to test compounds for 1 h only, *i.e.* a period during which the conjugates were shown to be metabolically stable under the conditions of the assay procedures (refer *Examples 41 & 42*). IC₅₀ values for 1-h and 3-d exposures are summarised in *Table 6* and are compared with those obtained with free paclitaxel. It should be noted that due to the 15 negligible water-solubility of unconjugated paclitaxel, washing off of compound not internalised into the cells after exposure was much less effective than for the conjugates, which have solubility in physiological media of > 10 mg/mL. It can be concluded that for the 1-h exposure results, the full cytotoxic activity can be attributed to the intact paclitaxel-conjugates (refer also *Example 37*).

20 *Assay procedure* – Cells were seeded into 96-well plates at 2,500 cells per well in DMED, containing 10 % FCS and antibiotics. After overnight incubation, test compounds were prepared as dilution series in cell medium (addition of dimethylsulfoxide in the case of free paclitaxel to effect partial dissolution) and were 25 added to the cells. For the 1-h exposure samples, incubation was continued for 1 h, cell culture medium supernatants were removed and the wells were further washed with cell culture medium (5 x 2 min). Total viable cells were quantitated after a total of 72 h incubation using a standard MTT-assay.

Table 6

Test compound	72-h IC ₅₀ (μM)			
	Cell line			
	A549		MCF7	
	Exposure time			
	1 h	3 d	1 h	3 d
Paclitaxel	0.028	< 0.015	0.04	< 0.015
Paclitaxel-(16mer vector) conjugate	0.618	< 0.015	0.202	0.017
Paclitaxel-(7mer vector) conjugate	0.043	< 0.015	0.325	< 0.015

5 Example 44**Evaluation of paclitaxel- and podophyllotoxin-vector conjugates in carcinoma cell line panel**

10 Serial dilutions of test compounds (*Table 7*: 2'-paclitaxel vector conjugate, 2'-[succinimidopropionoyl-(H-Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-OH)]paclitaxel; 7-paclitaxel vector conjugate, 7-[succinimidopropionoyl-(H-Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-OH)]paclitaxel; 4-podophyllotoxin vector conjugate, 4-[Succinimidopropionoyl-(H-Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-OH)]podophyllotoxin) were applied to the cell lines. After incubation for 96 h, cytotoxicity was assessed using a standard SRB-assay.

Table 7. 96-h IC₅₀ (µM) cytotoxicity evaluation in cell line panel

Cell Line	Vector	2'-Paclitaxel Vector Conjugate	7-Paclitaxel Vector Conjugate	Paclitaxel	4-Podophyllotoxin Vector Conjugate	Etoposide
BE	> 25	0.0305	1.6	< 0.0025	0.55	1.1
COLO205	> 25	0.074	1.9	0.0026	0.495	0.8
DLD-1	> 25	0.6	25	0.054	0.65	0.57
HCT116	> 25	0.096	2.4	< 0.0025	0.53	1.9
HT29	> 25	0.092	2.25	< 0.0025	0.53	2.6
KM12	> 25	0.105	2.95	0.0028 5	0.58	0.58
LIM1215	> 25	0.12	3.65	0.0058	1.1	0.33
LS174T	> 25	0.195	7.4	0.0085	1.25	0.46
A2780	> 25	0.105	2.8	< 0.0025	0.54	0.21
A2780Cis ^K	> 25	0.125	4.3	0.0051	0.54	0.68
CH1	> 25	0.115	6.6	0.0041 5	0.51	0.165
CH1Dox ^K	> 25	4.6	> 25	0.54	0.51	6.6
CH1Taxol ^K	> 25	0.13	8.7	0.0058	0.52	0.145
SKOV-3	> 25	0.235	22	0.01	0.74	13

5

Example 45**Evaluation of etoposide and podophyllotoxin derivatives in topoisomerase II****10 inhibition assay**

Topoisomerase II assay – Plasmid DNA (0.3 µg) was incubated at 37 °C with 4 units of purified recombinant human topoisomerase II in cleavage buffer (30 mM Tris.HCl, pH 7.6, 60 mM NaCl, 3 mM ATP, 15 mM mercaptoethanol, 8 mM MgCl₂) with or without the addition of test compound (at 1mM, 100 µM, or 10 µM final concentration). Reactions were stopped by the immediate addition of SDS (1 % w/v final). Samples were treated with proteinase K (30 min at 37 °C) and extracted twice

with an equal volume of 42:1 CHCl₃/i-amyl alcohol. After adding loading dye, samples were loaded to a 4 x TAE, 1 % agarose gel containing 0.5 mg/mL ethidium bromide and electrophoresed for 16 – 24 h. Topoisomerase II inhibition was judged by the production of linear plasmid DNA, representing trapped cleavage intermediate, and 5 by the ratio of substrate (supercoiled DNA) to product (relaxed DNA). A relaxation assay was performed identically, except that the reaction buffer was optimised for the detection of catalysis rather than cleavage, *i.e.* only 2 units of enzyme were used per sample. The reaction buffer was 50 mM Tris.HCl, pH 8, 120 mM KCl, 0.5 mM ATP, 0.5 mM dithiothreitol, 10 mM MgCl₂. Topoisomerase II inhibition was judged by the 10 ratio of substrate (supercoiled DNA) to product (relaxed DNA).

Table 8

Test Compound	Activity observed ^a
Etoposide	IC
Podophyllotoxin	-
4'-Demethylepipodophyllotoxin	IC
4'-Demethyl-4-(4"-aminoanilino)epipodophyllotoxin	I
H-βAla-Arg-Arg-Met-Lys-Trp-Lys-Lys-NH ₂	-
4-[Succinimidopropionoyl-(H-Cys-βAla-Arg-Arg-Met-Lys-Trp-Lys-Lys-NH ₂)]podophyllotoxin	-
4'-[Succinimidopropionoyl-(H-Cys-βAla-Arg-Arg-Met-Lys-Trp-Lys-NH ₂)]epipodophyllotoxin	IC
4'-Demethyl-4-[acetyl-(H-Cys-βAla-Arg-Arg-Met-Lys-Trp-Lys-NH ₂)]epipodophyllotoxin	IC
4'-Demethyl-4-[4"-aminoanilino-(succinimidopropionoyl)-(H-Cys-βAla-Arg-Arg-Met-Lys-Trp-Lys-NH ₂)]epipodophyllotoxin	I

a) I denotes inhibition of relaxation of supercoiled plasmid by topoisomerase II. C denotes accumulation of topoisomerase II reaction intermediate.

Abbreviations

Boc	<i>tert</i> -Butyloxycarbonyl
Bu ^t	<i>tert</i> -Butyl
CF ₃ COOH	Trifluoroacetic acid
5 CH ₂ Cl ₂	Dichloromethane
DE MALDI-TOF MS	Delayed extraction matrix-assisted laser desorption ionisation time-of-flight mass spectrometry
DMF	<i>N,N</i> -Dimethylformamide
Et ₂ O	Diethyl ether
10 Fmoc	9-Fluorenylmethyloxycarbonyl
HMBA	<i>p</i> -Hydroxymethylbenzoyl
HOBt	1-Hydroxybenzotriazole
MeCN	Acetonitrile
Pmc	2,2,5,7,8-Pentamethylchroman-6-sulphonyl
15 Pr ₂ NEt	<i>N,N</i> -Diisopropylethylamine
PyBOP	Benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate
RP-HPLC	Reversed-phase high performance liquid chromatography
Trt	Trityl (triphenylmethyl)

20

Example 1a

H-Arg(Pmc)-Gln(Trt)-Ile-Lys(Boc)-Ile-Trp-Phe-Gln(Trt)-Asn(Trt)-Arg(Pmc)-
Arg(Pmc)-Met-Lys(Boc)-Trp-Lys(Boc)-Lys(Boc)-Resin

25 Peptide assembly was performed using an ABI 433A Peptide Synthesizer (Perkin-Elmer Applied Biosystems). A standard synthesis protocol ("FastMoc 0.25 mmol MonPrevPk") was applied. The starting resin was Fmoc-Lys(Boc)-[(4-(hydroxymethyl)phenoxyacetyl)-Resin] (ABI 401425; 0.5 mmol/g). The final peptidyl resin (1.37 g; 100 %) was washed with Et₂O and dried *in vacuo*.

30

In order to demonstrate the chemical integrity of this intermediate, a small aliquot of peptidyl resin was cleaved and deprotected, followed by analysis of the crude product H-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-OH, which revealed purity of > 90 % (anal. RP-HPLC) and chemical identity (DE MALDI-TOF 5 MS and quantitative amino acid analysis).

[H-Glu(OBu¹)-Gly-bAla]₄-Lys₂-Lys-bAla-Arg(Pmc)-Gln(Trt)-Ile-Lys(Boc)-Ile-Trp-Phe-Gln(Trt)-Asn(Trt)-Arg(Pmc)-Arg(Pmc)-Met-Lys(Boc)-Trp-Lys(Boc)-Lys(Boc)-Resin

10 The above peptidyl resin (137 mg, 0.025 mmol) was acylated with Fmoc-bAla-OH (47 mg, 0.15 mmol), PyBOP (78 mg, 0.15 mmol), HOEt (20 mg, 0.15 mmol) and PrⁱNEt (39 mL, 0.225 mmol) in DMF (2 mL) during 2 h. It was then Fmoc-deprotected with 20 % piperidine in DMF for 20 min and washed extensively with DMF. The product was further extended by two successive acylation and deprotection cycles using Fmoc-15 Lys(Fmoc)-OH (0.15 mmol in first cycle; 0.3 mmol in second cycle) using similar coupling and deprotection steps. This was followed by further chain extension with Fmoc-Gly-OH (0.6 mmol) and Fmoc-Glu(OBu¹)-OH (0.6 mmol), again using similar acylation and Fmoc-deprotection conditions. The product was Fmoc-deprotected and washed extensively with DMF, CH₂Cl₂ and Et₂O, followed by drying *in vacuo*.

20 In order to demonstrate chemical integrity of this intermediate, a small aliquot of peptidyl resin was cleaved and side-chain deprotected, followed by analysis of the crude product [H-Glu-Gly-bAla]₄-Lys₂-Lys-bAla-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-OH, which revealed purity (> 89 %; RP-HPLC on 25 Vydac 218TP54, 1 mL/min, 25 °C, 15 – 25 % MeCN in 0.1 % aq CF₃COOH over 20 min, t_R = 17.7 min, λ = 200 - 300 nm) and identity (DE MALDI-TOF MS: [M + H]⁺ = 3732, C₁₆₅H₂₆₉N₅₃O₄₄S = 3731.30).


30 {[4[N-(2,4-diamino-6-pteridinyl-methyl)-N-methylamino]benzoyl]-Glu(OBu¹)-Gly-bAla}₄-Lys₂-Lys-bAla-Arg(Pmc)-Gln(Trt)-Ile-Lys(Boc)-Ile-Trp-Phe-

Gln(Trt)-Asn(Trt)-Arg(Pmc)-Arg(Pmc)-Met-Lys(Boc)-Trp-Lys(Boc)-Lys(Boc)-Resin

The above peptidyl resin (76 mg, 0.025 mmol) was reacted overnight at room temperature with 4[N-(2,4-diamino-6-pteridinyl-methyl)-N-methylamino]benzoic acid

5 hemihydrochloride dihydrate (Aldrich 86;155-3; 76 mg, 0.2 mmol) and PyBOP (104 mg, 0.2 mmol), HOBr (27 mg, 0.2 mmol) and Pr₂NEt (70 mL, 0.4 mmol) in DMF (2 mL). The product was washed successively with DMF, CH₂Cl₂ and Et₂O and dried *in vacuo* to afford the title compound (85 mg orange peptidyl resin).

10 {[4[N-(2,4-diamino-6-pteridinyl-methyl)-N-methylamino]benzoyl]-Glu-Gly-bAla}₄-Lys₂-Lys-bAla-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-OH



15

The above product was treated for 1.5 h at room temperature with phenol / H₂O / thioanisole / 1,2-dithioethane / CF₃COOH, 0.75 : 0.5 : 0.5 : 0.25 : 10, (12 mL). Resin residue was then filtered off and washed on a sinter with small aliquots of neat CF₃COOH. The combined filtrate and washings were treated with Et₂O (100 mL) and cooled. The precipitated product was collected by centrifugation and the ethereal supernatant was decanted. The product was washed three more times with Et₂O in a similar fashion. The final crude product was dried *in vacuo* (61 mg orange powder). This material was redissolved in 4 mL 0.1 % aq CF₃COOH and filtered. The resulting solution was applied (two separate runs) to an RP-HPLC column (Vydac 218TP1022; 22 x 250 mm). The column was eluted at 9 mL/min using a gradient from 17.5 to 27.5

% MeCN in 0.1 % aq CF₃COOH over 40 min (25 °C). Peak fractions were collected, monitored (analytical RP-HPLC) and pooled as appropriate. After vacuum centrifugation, pure title compound (13.5 mg) was obtained. Anal. RP-HPLC: t_R = 17.8 min (Vydac 218TP54, 17.5 – 27.5 % MeCN in 0.1 % aq CF₃COOH over 20 min, 5 1 mL/min, 25 °C; purity > 99 %, λ = 200 - 300 nm). DE MALDI-TOF MS: [M + H]⁺ = 4962 (C₂₂₅H₃₂₁N₈₁O₄₈S = 4960.54).

Example 2a

10 H-Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-OH
H-Arg(Pmc)-Gln(Trt)-Ile-Lys(Boc)-Ile-Trp-Phe-Gln(Trt)-Asn(Trt)-Arg(Pmc)-
Arg(Pmc)-Met-Lys(Boc)-Trp-Lys(Boc)-Lys(Boc)-Resin (see example 1; 411 mg,
0.075 mmol) was acylated with Fmoc-Cys(Trt)-OH (264 mg, 0.45 mmol), PyBOP
(234 mg, 0.45 mmol), HOBr (61 mg, 0.45 mmol) and Pr₂N*Et* (0.12 mL, 0.675 mmol)
15 in DMF (3 mL) during 3 h. The resulting peptidyl resin was washed with DMF (3 x 5
min, 25 mL each), drained and treated with 20 % piperidine in DMF during 20 min.
After filtration of the reagent, the product H-Cys(Trt)- Arg(Pmc)-Gln(Trt)-Ile-
Lys(Boc)-Ile-Trp-Phe-Gln(Trt)-Asn(Trt)-Arg(Pmc)-Arg(Pmc)-Met-Lys(Boc)-Trp-
Lys(Boc)-Lys(Boc)-Resin was washed successively with DMF, CH₂Cl₂ and Et₂O,
20 before being dried *in vacuo*.


The above product was treated for 2 h at room temperature with phenol / H₂O /
thioanisole / 1,2-dithioethane / CF₃COOH, 0.75 : 0.5 : 0.5 : 0.25 : 10 (12 mL). Resin
residue was then filtered off and washed on a sinter with small aliquots of neat
25 CF₃COOH. The combined filtrate and washings were treated with Et₂O (100 mL) and
cooled. The precipitated product was collected by centrifugation and the ethereal
supernatant was decanted. The product was washed three more times with Et₂O in a
similar fashion. The final crude product was dried *in vacuo* (238 mg). An aliquot (119
mg) of this material was redissolved in 2 mL 0.1 % aq CF₃COOH and filtered. The
30 resulting solution was applied to an RP-HPLC column (Vydac 218TP1022; 22 x 250
mm). The column was eluted at 9 mL/min using a gradient from 17.5 to 27.5 %

MeCN in 0.1 % aq CF₃COOH over 40 min (25 °C). Peak fractions were collected, monitored (analytical RP-HPLC) and pooled as appropriate. After vacuum centrifugation, pure title compound (60.9 mg) was obtained. Anal. RP-HPLC: t_R = 15.8 min (Vydac 218TP54, 17.5 – 27.5 % MeCN in 0.1 % aq CF₃COOH over 20 min, 5 1 mL/min, 25 °C; purity > 99 %, λ = 214 nm). DE MALDI-TOF MS: [M + H]⁺ = 2351 (C₁₀₇H₁₇₃N₃₅O₂₁S₂ = 2349.87).

N-[3-(Maleimido)benzoyl]-doxorubicin

Doxorubicin hydrochloride (Aldrich, 86,036-0; 5.9 mg, 0.01 mmol) was dissolved in 10 H₂O (1 mL) and DMF (0.5 mL). Buffer (0.1 M aq phosphate, pH 7.2; 0.5 mL) was added with stirring. To the resulting suspension 3-maleimidobenzoic acid *N*-hydroxysuccinimide ester (Sigma, M2786; 12.9 mg, 0.04 mmol) in DMF (1 mL) was added dropwise. The red-coloured reaction mixture cleared temporarily and after *ca.* 10 min precipitation was observed. Reaction progress was monitored by anal. RP- 15 HPLC and after 2 h all doxorubicin had reacted. The mixture was then diluted with H₂O (1.5 mL), cooled to 4 °C and centrifuged. The supernatant was decanted. The residual pellet was redissolved in DMF (1 mL) and diluted with 0.1 % aq CF₃COOH (2 mL). This solution was applied to a solid-phase extraction cartridge (LiChrolut RP- 20 18, 500 mg; Merck); the cartridge was washed with 0.1 % aq CF₃COOH (4 mL) and eluted with 6 : 4 MeCN / H₂O (containing 0.1 % CF₃COOH) in two fractions (2 x 4 mL). The first fraction contained the title compound and was used directly in the next step.

25 **N-[3-{3-(Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-
Lys-OH)succinimido}benzoyl]-doxorubicin**



The above *N*-[3-(Maleimido)benzoyl]-doxorubicin solution was diluted with DMF (1 mL) and Et₃N (50 mL) was added. The solution turned dark brown. H-Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-OH (5 mg), dissolved in DMF (1 mL) was then added. The mixture was stirred and the brown colour was observed to discharge, leaving a light red solution. The reaction was monitored by anal. RP-HPLC. After 1.5 h, all 3-(maleimido-benzoyl)-doxorubicin had reacted. The solution was acidified with AcOH (0.5 mL), diluted with H₂O (3 mL) and applied to a solid-phase extraction cartridge (LiChrolut RP-18, 500 mg; Merck). The cartridge was washed with 0.1 % aq CF₃COOH (6 mL) and eluted (6 mL of 6 : 4 MeCN / H₂O (containing 0.1 % CF₃COOH)). The eluate was dried by vacuum centrifugation. The residue was redissolved in 0.1 % aq CF₃COOH (2 mL), filtered and applied to an RP-HPLC column (Vydac 218TP1022; 22 x 250 mm). The column was eluted at 9 mL/min using a gradient from 20 to 40 % MeCN in 0.1 % aq CF₃COOH over 40 min (25 °C). Peak fractions were collected, monitored (analytical RP-HPLC) and pooled as appropriate. After vacuum centrifugation, pure title compound (1.2 mg) was obtained. Anal. RP-HPLC: *t*_R = 15.6 & 15.8 (partly resolved thioether diastereomers) min (Vydac 218TP54, 0 - 60 % MeCN in 0.1 % aq CF₃COOH over 20 min, 1 mL/min, 25 °C; purity > 95 %, *l* = 200 - 300 nm). DE MALDI-TOF MS: [M + H]⁺ = 3094, [M + 2 H]²⁺ = 1548 (C₁₄₅H₂₀₇N₃₇O₃₅S₂ = 3092.56).

20


Example 3a

2'-[(3-Maleimidopropionoyl)]-paclitaxel

3-Maleimidopropionic acid (5.7 mg, 0.034 mmol) was dissolved in dry CH_2Cl_2 (0.5 mL). The mixture was stirred and diisopropylcarbodiimide (2.4 mg, 0.019 mmol) in dry CH_2Cl_2 (0.5 mL) was added. The reaction was allowed to proceed with stirring for 30 min. Solvent was then removed under reduced pressure. The residue of 3-maleimidopropionic acid anhydride was redissolved in dry pyridine (0.5 mL). A solution of paclitaxel (Aldrich 41,701-7; 1 mg, 0.0012 mmol) in dry pyridine (0.5 mL) was added and the mixture was stirred under N_2 for 3 h. It was then evaporated to dryness under reduced pressure. The residue was treated with H_2O (1.5 mL). After 10

min, it was extracted with CH_2Cl_2 (3×5 mL). The combined extracts were washed with H_2O (3×1 mL), dried with MgSO_4 , filtered and evaporated to dryness to leave a white residue of the title compound.

5 **2'-{3-[3-(Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-OH)succinimido]propionoyl}-paclitaxel**



10 The product from the previous reaction was redissolved in DMF (0.25 mL) and H-Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-OH (2.5 mg, 0.0011 mmol), dissolved in DMF (0.25 mL) was then added, together with Et_3N (ca. 0.05 mL). The mixture was stirred under N_2 and was monitored by anal. RP-HPLC. After 45 min, the reaction was complete. The mixture was diluted to 2 mL with 0.1 % aq CF_3COOH , filtered and applied to an RP-HPLC column (Vydac 218TP1022; 22 x 250 mm). The column was eluted at 9 mL/min using a gradient from 0 to 60 % MeCN in 0.1 % aq CF_3COOH over 40 min (25 °C). Peak fractions were collected, monitored (analytical RP-HPLC) and pooled as appropriate. After vacuum centrifugation, pure title compound (1.2 mg) was obtained. Anal. RP-HPLC: $t_R = 17.4$ & 17.5 (partly resolved thioether diastereomers) min (Vydac 218TP54, 0 - 60 % MeCN in 0.1 % aq CF_3COOH over 20 min, 1 mL/min, 25 °C; purity > 95 %, $\lambda = 200 - 300$ nm). DE MALDI-TOF MS: $[\text{M} + \text{H}]^+ = 3356$, $[\text{M} + 2 \text{ H}]^{2+} = 1679$ ($\text{C}_{161}\text{H}_{229}\text{N}_{37}\text{O}_{38}\text{S}_2 = 3354.90$).

Example 4a

5 *In vitro* cytotoxic activity of {[4[N-(2,4-diamino-6-pteridinyl-methyl)-N-methylamino] benzoyl]-Glu-Gly-bAla}₄-Lys₂-Lys-bAla-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-OH

10 This compound (abbreviated 'MTX-Pen' in tables below) was evaluated for its ability to inhibit cell proliferation of normal (immortalised) human cells (HaCaT cells, *Tables 1 & 2*) and a human colorectal cancer cell line (HT29, *Table 3*). The free drug methotrexate (*Tables 1 – 3*) and the free vector H-Ala-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys-OH (abbreviated 'Pen' in *Table 1* below) were included for the purposes of comparison.

15 *Assay procedure* – Cells were seeded into 96-well plates at 2,500 cells/well in DMEM with 10 % foetal calf serum and antibiotics. After overnight incubation, test compound dilutions in cell medium were prepared and were added to the cells. Samples were taken 1, 2, 3, and 4 days after compound addition. Nucleotide Releasing Reagent (LumiTech ViaLight kit) was added in order to lyse the cells and release ATP. After incubation at room temperature (5 min), the mixtures were transferred to opaque 96-well plates and stored at –20 °C until analysis. After loading plates into a luminometer (Lucy 1, Labtech International), ATP Monitoring Reagent (20 mL/well, LumiTech 20 ViaLight kit) was added to each well successively and light intensity was measured immediately. Six readings were taken per sample. Each assay point was established using six replicates and appropriate controls. ATP bioluminescence was found to be 25 proportional to viable cell count over the entire cells/well range used.

Statistically significant results in the tables below are printed in bold face.

Table 1 (HaCaT Cells)

Dose (μ M)	% Cell Death														
	Day 1				Day 2				Day 3				Day 4		
	MTX	MTX-	Pen	Pen	MTX	MTX-	Pen	Pen	MTX	MTX-	Pen	Pen	MTX	MTX-	Pen
40.0	4	29	16	16	15	82	-22	-22	79	97	5	5	92	98	12
13.3	22	-42	18	18	35	63	0	0	82	97	-17	-17	92	98	-6
4.4	4	-8	8	8	24	45	-4	-4	77	95	-1	-1	93	98	10
1.5	13	-24	16	16	31	82	-31	-31	77	82	2	2	94	88	-14
0.5	-4	-19	6	6	31	2	-6	-6	75	29	-29	-29	93	49	-26
0.2	7	14	26	26	11	21	0	0	79	20	-3	-3	93	51	21

5 Table 2 (HaCaT Cells)


Dose (μ M)	% Cell Death											
	Day 1		Day 2		Day 3		Day 4					
	MTX	MTX-	MTX	MTX-	MTX	MTX-	MTX	MTX-	MTX	MTX-	MTX	MTX-
40.0		42			88		95		94			
13.3		27			87		95		94			
4.4	21	15	70	52	97	95	92	88				
1.5	14	19	67	12	96	-16	91	17				
0.5	0	13	59	24	96	-27	91	2				
0.2	3		41		94		86					
0.1	19		7		45		65					

Table 3 (HT 29 Cells)

Dose (μ M)	% Cell Death											
	Day 1		Day 2		Day 3		Day 4					
	MTX	MTX-	MTX	MTX-	MTX	MTX-	MTX	MTX-	MTX	MTX-	MTX	MTX-
40.0		31			79		96		98			
13.3		3			45		88		96			
4.4	-14	10	-4	6	58	46	86	77				
1.5	17	16	-5	9	48	15	84	45				
0.5	15	14	-12	8	52	17	88	16				
0.2	10		-5		54		85					
0.1	6		-17		52		84					


Example 5a

[(3-Maleimidopropionoyl)]bohemine



3-Maleimidopropionic acid (12.8 mg, 76 mmol) was dissolved in CH_2Cl_2 (1 mL). The 5 mixture was stirred and DIC (5.3 mg, 42 mmol) in dry CH_2Cl_2 (0.5 mL) was added. The reaction was allowed to proceed with stirring for 40 min. Solvent was then removed under reduced pressure. The residue of 3-maleimidopropionic acid anhydride was redissolved in dry pyridine (0.5 mL). A solution of bohemine ({6-(benzylamino)-2-[(3-(hydroxypropyl)amino]9-isopropylpurine}, 10.3 mg, 30 mmol) and DMAP (0.35 mg, 2 mmol) in dry pyridine (0.5 mL) was added and the mixture was stirred under N_2 10 for 1 h. It was then evaporated to dryness under reduced pressure. The residue was redissolved in DMF (1 mL) and applied to an RP-HPLC column (Vydac 218TP1022; 22x250mm). The column was eluted at 9mL/min using a gradient from 10 - 60 % MeCN gradient in 0.1% aq. CF_3COOH over 40min (25°C). Peak fractions were 15 collected, monitored (Anal. RP-HPLC) and pooled as appropriate. After vacuum centrifugation, pure title compound (14.7 mg, 87.8 %) was obtained. Anal. RP-HPLC: $t_{\text{R}} = 17.7$ min (column (Vydac 218TP54, 0 - 60 % MeCN in 0.1% aq. CF_3COOH over 20min, 1mL/min., 25°C; purity > 95 %, $\lambda=200\text{-}300\text{nm}$). $^1\text{H-NMR}$ (CDCl_3) and DE MALDI-TOF MS spectra were consistent with the proposed structure ($\text{C}_{25}\text{H}_{29}\text{N}_7\text{O}_4 = 20$ 491.54).

***O*-{3-[3-(Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-OH)succinimido]propionoyl}-bohemine**



5 The product from the previous reaction (0.74 mg, 1.5 mmol) was dissolved in DMF (0.3 mL) and Et₃N (50 mL) was added. H-Cys-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-OH (3.5 mg, 1.5 mmol), dissolved in DMF (0.25 mL) was then added. The mixture was stirred under N₂ and was monitored by anal. RP-HPLC. After 1 h, the reaction was complete. The mixture was filtered and applied to an RP-HPLC column (Vydac 218TP1022; 22x250mm). The column was eluted at 9mL/min using a gradient from 10 - 60 % MeCN gradient in 0.1% aq. CF₃COOH over 40min (25°C). Peak fractions were collected, monitored (Anal. RP-HPLC) and pooled as appropriate. After vacuum centrifugation, pure title compound (1.7 mg, 40 %) was obtained. Anal. RP-HPLC: t_R = 15.0 min (Vydac 218TP54, 0 - 60 % MeCN in 0.1% aq. CF₃COOH over 20min, 1mL/min., 25°C; purity > 95 %, λ=200-300nm). DE MALDI-TOF MS: [M + H]⁺ = 2842 (C₁₃₂H₂₀₂N₄₂O₂₅S₂ = 2841.42).

10

15

CLAIMS

1. A delivery system comprising a drug moiety linked to a carrier moiety, wherein the carrier moiety comprises a homeobox peptide or a fragment or derivative thereof.

5

2. A delivery system according to claim 1, wherein the drug moiety is a therapeutically active non-peptide, non-oligonucleotide drug.

3. A delivery system according to any preceding claim, wherein the delivery system is therapeutically active in its intact state.

10 4. A delivery system according to any preceding claim, wherein the homeobox peptide is derived from the helix 3 sequence of a homeobox peptide or a fragment or derivative thereof.

15

5. A delivery system according to claim 4, wherein the homeobox peptide is derived from the pAntp peptide or a fragment or derivative thereof.

6. A delivery system according to claims 4 or 5, wherein the carrier moiety is penetratin, or a fragment or derivative thereof.

20 7. A delivery system according to claim 6, wherein the carrier moiety is SEQ ID No. 1.

25 8. A delivery system according to claim 6, wherein the carrier moiety is a truncated form of SEQ ID No. 1.

9. A delivery system according to claim 6 or 8, wherein the carrier moiety is SEQ ID No. 2.

30

10. A delivery system according to any of claims 6 to 9, wherein the free carboxyl group of the carrier moiety carboxy terminal amino acid residue is converted into an carboxamide group.

5 11. A delivery system according to any of claims 4 to 10, wherein the homeobox peptide is comprised of D-amino acids.

12. A delivery system according to any preceding claim, wherein the drug moiety is derived from a cytotoxic drug.

10 13. A delivery system according to claim 12, wherein the drug moiety is selected from DNA damaging agents, anti-metabolites, anti-tumour antibiotics, natural products and their analogues, dihydrofolate reductase inhibitors, pyrimidine analogues, purine analogues, cyclin-dependent kinase inhibitors, thymidylate synthase inhibitors, DNA intercalators, DNA cleavers, topoisomerase inhibitors, anthracyclines, vinca drugs, mitomycins, bleomycins, cytotoxic nucleosides, pteridine drugs, diarylenes, podophyllotoxins, platinum containing drugs, differentiation inducers and taxanes.

15 14. A delivery system according to claim 13, wherein the drug moiety is selected from methotrexate, methopterin, dichloromethotrexate, 5-fluorouracil, 6-mercaptopurine, tri-substituted purines such as olomoucine, roscovitine and bohemine, flavopiridol, staurosporin, cytosine arabinoside, melphalan, leurosine, actinomycin, daunorubicin, doxorubicin, mitomycin D, mitomycin A, carminomycin, aminopterin, tallysomycin, podophyllotoxin (and derivatives thereof), etoposide, cisplatin, carboplatin, vinblastine, vincristine, vindesine, paclitaxel, docetaxel, taxotere 25 retinoic acid, butyric acid, acetyl spermidine, tamoxifen, irinotecan and camptothecin.

20 15. A delivery system according to claim 14, wherein the drug moiety is selected from methotrexate, podophyllotoxin (and derivatives thereof), etoposide, camptothecin, paclitaxel, doxorubicin, roscovitine and bohemine.

16. A delivery system according to any preceding claim, wherein the drug moiety is directly linked to the carrier moiety.
17. A delivery system according to any of claims 1 to 15, wherein the drug moiety is indirectly linked to the carrier moiety by means of a linker moiety.
18. A delivery system according to claim 17, wherein the linker moiety is selected from (methylamino)benzoyl-Cys, succinimidobenzoyl-Cys, succinimidopropionoyl-Cys, succinimidobenzoyl-Cys, β -alanyl-succinyl, acetyl-Cys and (4"-aminoanilino)-succinimidopropionoyl-Cys.
19. A delivery system according to any preceding claim, wherein each carrier moiety bears more than one drug moiety.
- 15 20. A delivery system according to claim 19, wherein the drug moieties are different.
21. A delivery system according any of claims 19 or 20, wherein each drug moiety is linked to the carrier moiety by way of a linker moiety.
- 20 22. A delivery system according to claim 21, wherein each drug moiety is linked to the carrier moiety by an identical linker moiety.
23. A delivery system according to claim 21, wherein each drug moiety is linked to the carrier moiety by a different linker moiety.
24. A delivery system according to claim 22, wherein the more than one drug moieties are attached to the carrier by a network of lysine residues.
- 30 25. A delivery system according to any of claims 21 to 23, wherein the more than one drug moieties are attached to the carrier by a linker moiety selected from

(methylamino)benzoyl-Cys, succinimidobenzoyl-Cys, succinimidopropionoyl-Cys, succinimidobenzoyl-Cys, β -alanyl-succinyl, acetyl-Cys and (4"-aminoanilino)-succinimidopropionoyl-Cys.

5 26. A delivery system according to claim 25 wherein the linker moiety is succinimidopropionoyl-Cys.

10 27. A delivery system according to claim 25, wherein the carrier moiety is a truncated form of penetratin and the linker further includes from 1 to 4 amino acid residues.

28. A delivery system according to claim 27, wherein the amino acid residues are selected from residues of cysteine, glycine glutamic acid and β -alanine.

15 29. A delivery system according to any preceding claim, further comprising a targetting moiety.

30. A delivery system according to claim 27, wherein the targetting moiety is attached to the carrier moiety.

20 31. A delivery system according to claim 27, wherein the targetting moiety is attached to the drug moiety.

25 32. A macromolecule selected from any of the delivery systems defined in any preceding claim.

33. A macromolecule selected from the delivery systems;

#	Drug moiety	Linker moiety	Carrier moiety
	(methotrexate) ₄	((methylamino)benzoyl-EG β A) ₄	(L) ₃ BARQIKIWFQNRRMKWKK-OH
	doxorubicin	succinimidobenzoyl-C	RQIKIWFQNRRMKWKK-OH
	doxorubicin	succinimidobenzoyl-C	(D-K)(D-K)(D-W)(D-K)(D-M)(D-R)(D-R)(D-N)(D-Q)(D-F)(D-W)(D-I)(D-K)(D-I)(D-Q)(D-R-NH ₂)
	paclitaxel	2'-succinimidopropionoyl-C	RQIKIWFQNRRMKWKK-OH
N-term C-term	pactitaxel carboxyfluorescein	2'-succinimidopropionoyl-GCG β A	RQIKIWFQNRRMKWKK
	paclitaxel	2'-succinimidopropionoyl-C	RQIKIWFQNRRMKWKK-NH ₂
	paclitaxel	2'-succinimidopropionoyl-C β A	RRMKWKK-NH ₂
	paclitaxel	7-succinimidopropionoyl-C	RQIKIWFQNRRMKWKK-OH
	podophyllotoxin	4-succinimidopropionoyl-C	RQIKIWFQNRRMKWKK-OH
N-term C-term	podophyllotoxin biotinamidocaproyl	4-succinimidopropionoyl-GCG β A	RQIKIWFQNRRMKWKK
	podophyllotoxin	4-succinimidopropionoyl-C	RQIKIWFQNRRMKWKK-NH ₂
	podophyllotoxin	4-succinimidopropionoyl-C	(D-R)(D-Q)(D-I)(D-K)(D-I)(D-W)(D-F)(D-Q)(D-N)(D-R)(D-R)(D-M)(D-K)(D-W)(D-K)(D-K-NH ₂)
	podophyllotoxin	4-succinimidopropionoyl-C β A	RRMKWKK-NH ₂
	podophyllotoxin	4-succinimidopropionoyl-C β A	(D-R)(D-R)(D-M)(D-K)(D-W)(D-K)(D-K-NH ₂)
	epipodophyllotoxin	4'-succinimidopropionoyl-C	RQIKIWFQNRRMKWKK-OH
	epipodophyllotoxin	4'-succinimidopropionoyl-C	RQIKIWFQNRRMKWKK-NH ₂
	epipodophyllotoxin	4'-succinimidopropionoyl-C β A	RRMKWKK-NH ₂
	4'-demethyl epipodophyllotoxin	4-succinimidopropionoyl-C	RQIKIWFQNRRMKWKK-OH
	etoposide (G2, G3 and 4')	succinimidopropionoyl-C	RQIKIWFQNRRMKWKK-OH
	roscovitine	succinimidopropionoyl-C	RQIKIWFQNRRMKWKK-OH
	bohemine	β A-succinyl- β A	RQIKIWFQNRRMKWKK-OH
	bohemine	succinimidopropionoyl-C	RQIKIWFQNRRMKWKK-OH
	podophyllotoxin	4-acetyl-C	RQIKIWFQNRRMKWKK-OH
	podophyllotoxin	4-acetyl-C β A	RRMKWKK-NH ₂
	4'-demethyl epipodophyllotoxin	4-acetyl-C β A	RRMKWKK-NH ₂
	4'-demethyl epipodophyllotoxin	4-acetyl-C	RQIKIWFQNRRMKWKK-NH ₂
	podophyllotoxin	4-succinimidopropionoyl-G β A	RRMKWKK-NH ₂

	camptothecin	10-O-succinimidopropionoyl-C	RQIKIWFQNRRMKWKK-NH ₂
C-term N-term	podophyllotoxin podophyllotoxin	4-succinimidopropionoyl-C 4-succinimidopropionoyl-C	RRMKWKK
N-term C-term	epipodophyllotoxin camptothecin	4'-succinimidopropionoyl-C 10-O-succinimidopropionoyl-C	RRMKWKK
N-term C-term	epipodophyllotoxin paclitaxel	4'-succinimidopropionoyl-C 2'-(succinimido)propionoyl-C	RRMKWKK
	4'-methoxy- epipodophyllotoxin	4-(4"-aminoanilino) succinimidopropionoyl-C	RQIKIWFQNRRMKWKK-NH ₂
	4'-methoxy- epipodophyllotoxin	4-(4"-aminoanilino) succinimidopropionoyl-C β A	RRMKWKK-NH ₂
	4'-demethyl- epipodophyllotoxin	4-(4"-aminoanilino) succinimidopropionoyl-C β A	RRMKWKK-NH ₂

34. A delivery system as defined herein with reference to the description or examples.




FIG. 1




FIG. 2



FIG. 4




FIG. 3

SEQUENCE LISTING

<110> Cyclacel Limited
Fischer, M Peter
Wang, Shudong

<120> Delivery System

<130> P004618WO NJN

<140> PCT/GB99/01957

<141> 1999-06-22

<150> GB 9814527.9

<151> 1998-07-03

<160> 27

<170> PatentIn Ver. 2.1

<210> 1

<211> 16

<212> PRT

<213> Drosophila melanogaster

<400> 1

Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys

1

5

10

15

<210> 2

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<400> 2

Arg Arg Met Lys Trp Lys Lys

1

5

<210> 3

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<400> 3

Asn Arg Arg Met Lys Trp Lys Lys

1

5

<210> 4

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<400> 4

Gln Asn Arg Arg Met Lys Trp Lys Lys

1

5

<210> 5
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 5
Phe Gln Asn Arg Arg Met Lys Trp Lys Lys
1 5 10

<210> 6
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 6
Lys Arg Met Lys Trp Lys Lys
1 5

<210> 7
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 7

Arg Lys Met Lys Trp Lys Lys
1 5

<210> 8

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<400> 8

Arg Arg Glu Lys Trp Lys Lys
1 5

<210> 9

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<400> 9

Arg Arg Gln Lys Trp Lys Lys
1 5

<210> 10
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<221> MOD_RES
<222> (3)
<223> Orn

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<400> 10
Arg Arg Xaa Lys Trp Lys Lys
1 5

<210> 11
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<400> 11
Arg Arg Met Lys Gln Lys Lys
1 5

<210> 12
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<400> 12
Arg Arg Met Lys Trp Phe Lys
1 5

<210> 13
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<221> MOD_RES
<222> (2)
<223> Orn

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<400> 13
Arg Xaa Arg Lys Trp Lys Lys
1 5

<210> 14
<211> 7
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<400> 14

Arg Arg Met Trp Lys Lys Lys

1 5

<210> 15

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<400> 15

Arg Arg Met Lys Lys Trp Lys

1 5

<210> 16

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> MOD_RES

<222> (4)

<223> bAla

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<400> 16

Leu Leu Leu Ala Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met

1

5

10

15

Lys Trp Lys Lys

20

<210> 17

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<400> 17

Cys Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys

1

5

10

15

Lys

<210> 18

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> MOD_RES

<222> (1)

<223> bAla

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<220>

<221> MOD_RES

<222> (20)

<223> AMIDATION

<400> 18

Ala Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys

1

5

10

15

Lys Gly Cys Gly

20

<210> 19

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<221> MOD_RES

<222> (2)

<223> bAla

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<220>

<221> MOD_RES

<222> (9)

<223> AMIDATION

10

<400> 19

Cys Ala Arg Arg Met Lys Trp Lys Lys

1

5

<210> 20

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<221> MOD_RES

<222> (1)

<223> bAla

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<400> 20

Ala Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys

1

5

10

15

Lys

<210> 21

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

11

<220>
<221> MOD_RES
<222> (9)
<223> AMIDATION

<400> 21
Cys Arg Arg Met Lys Trp Lys Lys Cys
1 5

<210> 22
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<400> 22
Ala Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys
1 5 10 15
Lys

<210> 23
<211> 19
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

12

<220>
<221> MOD_RES
<222> (19)
<223> AMIDATION

<400> 23

Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys
1 5 10 15

Gly Cys Gly

<210> 24
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<221> MOD_RES
<222> (1)
<223> bAla

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (8)
<223> AMIDATION

<400> 24

Ala Arg Arg Met Lys Trp Lys Lys
1 5

<210> 25
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (16)
<223> AMIDATION

<400> 25
Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys
1 5 10 15

<210> 26
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<221> MOD_RES
<222> (7)
<223> AMIDATION

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<400> 26
Arg Arg Met Lys Trp Lys Lys
1 5

<210> 27
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<221> MOD_RES
<222> (17)
<223> AMIDATION

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<400> 27
Cys Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys
1 5 10 15
Lys

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 99/01957

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K47/48

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>BRUGIDOU J ET AL: "The retro-inverso form of a homeobox-derived short peptide is rapidly internalised by cultured neurones: A new basis for an efficient intracellular delivery system" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 214, no. 2, 14 September 1995 (1995-09-14), pages 685-693, XP002087116 ISSN: 0006-291X cited in the application figure 1</p> <p>—</p>	1-7, 11
Y	<p>—</p> <p style="text-align: center;">-/-</p>	1-32

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the International filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the International filing date but later than the priority date claimed

- "T" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the International search

24 November 1999

Date of mailing of the International search report

03/12/1999

Name and mailing address of the ISA

European Patent Office, P.B. 6018 Patentdaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 661 epo nl
Fax: (+31-70) 340-3016

Authorized officer

Veronese, A

INTERNATIONAL SEARCH REPORT

In **ntional Application No**
PCT/GB 99/01957

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PROCHIANTZ A: "GETTING HYDROPHILIC COMPOUNDS INTO CELLS: LESSONS FROM HOMEOPEPTIDES" CURRENT OPINION IN NEUROBIOLOGY, vol. 6, no. 5, October 1996 (1996-10), pages 629-634, XP002910851 ISSN: 0959-4388 figures 1,2; table 2	1,3-7,11
Y		1-32
X	DATABASE SCISEARCH 'Online! 1998 DEROSSI D (REPRINT) ET AL: "Trojan peptides: the penetratin system for intracellular delivery" retrieved from STN Database accession no. 141940 XP002122131 abstract	1,3-7,11
Y	& TRENDS IN CELL BIOLOGY, (FEB 1998) VOL. 8, NO. 2, PP. 84-87. PUBLISHER: ELSEVIER SCI LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB. ISSN: 0962-8924., UMDS, GUYS HOSP, DEPT EXPT PATHOL, LONDON BRIDGE, LONDON SE1 9RT, ENGLAND (Reprint);UNIV PARIS 06, CNRS, URA 493, F-75252 PARIS 05, FRANCE; ECOLE NORMALE SUPER, CNRS, URA 1414, F-75230 PARIS 05, FRANCE	1-32
X	WO 91 18981 A (CENTRE NAT RECH SCIENT) 12 December 1991 (1991-12-12) cited in the application	1,3-8,11
Y	page 9, line 6-27; claims 4-10	1-32
Y	WO 97 12912 A (CENTRE NAT RECH SCIENT ;CHASSAING GERARD (FR); PROCHIANTZ ALAIN (F) 10 April 1997 (1997-04-10) cited in the application	1-32
Y	claim 6; tables 1,2	
Y	WO 97 19954 A (ASTA MEDICA AG) 5 June 1997 (1997-06-05) claims; examples 11-16,24-28	1-32
Y	WO 98 13059 A (SQUIBB BRISTOL MYERS CO) 2 April 1998 (1998-04-02) page 15, line 14 -page 18, line 10; claims	1-32
P,X	WO 99 05302 A (PERKIN ELMER CORP) 4 February 1999 (1999-02-04) claims; figures 3-5	1,3-7,11
		-/-

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 99/01957

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 99 11809 A (CRISANTI ANDREA ; IMP COLLEGE INNOVATIONS LIMITE (GB)) 11 March 1999 (1999-03-11) the whole document	1,3-7,11

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/GB 99/01957

Patent document cited in search report	Publication date	Patent family member(s)			Publication date
WO 9118981	A 12-12-1991	FR 2662698	A	06-12-1991	
		AT 143691	T	15-10-1996	
		DE 69122472	D	07-11-1996	
		DE 69122472	T	17-04-1997	
		EP 0485578	A	20-05-1992	
		JP 5502885	T	20-05-1993	
		PT 97877	A	30-04-1992	
WO 9712912	A 10-04-1997	FR 2739621	A	11-04-1997	
		EP 0797589	A	01-10-1997	
		JP 10510557	T	13-10-1998	
WO 9719954	A 05-06-1997	US 5843903	A	01-12-1998	
		AU 709539	B	02-09-1999	
		AU 7572296	A	19-06-1997	
		BR 9611647	A	23-02-1999	
		CA 2238574	A	05-06-1997	
		CN 1202903	A	23-12-1998	
		CZ 9801357	A	14-10-1998	
		EP 0863917	A	16-09-1998	
		NO 982252	A	15-05-1998	
		NZ 322054	A	29-04-1999	
		PL 326865	A	26-10-1998	
WO 9813059	A 02-04-1998	AU 4599597	A	17-04-1998	
WO 9905302	A 04-02-1999	AU 8408098	A	16-02-1999	
WO 9911809	A 11-03-1999	AU 8877698	A	22-03-1999	

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.